Podcasts about Lancet

Welcome to Top of The Morning with me Nelson John. Today: NHAI raises ₹46,000 crore through highway InvITs attracting global investors, BIS overhauls cybersecurity and wind energy standards, ED attaches more RCom properties amid ₹40,000 crore fraud probe, Delhi's air pollution crisis kills 1.72 million Indians annually per Lancet study, and the US approves $93 million defense deal for Javelin missiles and Excalibur rounds. Learn more about your ad choices. Visit megaphone.fm/adchoices

durée : 00:37:19 - Le 18/20 · Le téléphone sonne - Mercredi 19 novembre, une série d'articles scientifiques est publiée dans la revue “Lancet” sur les aliments ultratranformés qui démontrent leurs dangerosités pour la santé des consommateurs. Les enfants en sont la première cible. Comment inverser la tendance ? Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

In this can't-miss episode of The Food Professor Podcast, Michael LeBlanc and Sylvain Charlebois return with Part Two of their exclusive, final official interview with Michael Medline, former President & CEO of Empire/Sobeys. Medline offers unusually candid reflections on leadership, culture, vendor relationships, and the evolution of one of Canada's largest food retailers.The conversation opens with a deep dive into vendor relations and the Canadian Grocery Code of Conduct. Medline explains his early shock at the combative nature of vendor–retailer dynamics and details his personal commitment to transforming the ecosystem into one built on fairness, respect, and partnership. He reflects on how mentorship from industry leaders like Michael Graydon and collaboration with executives such as Mark Taylor helped advance the Code from concept to reality — ultimately becoming one of the proudest achievements of his tenure.Medline also shares rare behind-the-scenes reflections on working with the Sobey family, leading through disruption, and preparing the company for the next era of food retail. From AI-driven transformation to the duty of stewarding an organization with 129,000 teammates, he speaks openly about responsibility, succession, and what comes next in his career. His insights offer a masterclass in modern leadership during one of the most transformative decades in grocery retail.The episode also features a rich and timely news segment. Michael and Sylvain break down Health Canada's pause on cloned beef and swine approvals, a fast-moving story with major implications for transparency, labeling, science communication, and cross-border food integration. They examine why Canada's decision diverges from the U.S., where cloned-animal offspring have been permitted for nearly two decades — often without consumer awareness.The hosts then analyze the newest edition of the Canadian Food Sentiment Index, highlighting renewed concerns about food inflation, declining trust in grocers, shifting loyalty behaviours, and the end of Canada's “couponing era.” They explore evolving consumer habits, smarter comparison shopping, and the influence of younger digital-first generations.Other key topics include:• The Lancet's callout of ultra-processed foods — and why Sylvain believes the academic narrative is oversimplified.• The rapid rise of GLP-1 drugs and their early impact on grocery and foodservice behaviour.• Nutrien's reported decision to build a major potash terminal in Washington State rather than Canada.• The tangled story behind beef prices and the federal policies that may be limiting supply.• A big win for Canadian agriculture as GoodLeaf Farms raises $52 million to expand capacity and boost controlled-environment production. Go Here for the The Canadian Food Sentiment Index, Volume 2, no. 1  The Food Professor #podcast is presented by Caddle. About UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa. Michael LeBlanc is the president and founder of M.E. LeBlanc & Company Inc, a senior retail advisor, keynote speaker and now, media entrepreneur. He has been on the front lines of retail industry change for his entire career. Michael has delivered keynotes, hosted fire-side discussions and participated worldwide in thought leadership panels, most recently on the main stage in Toronto at Retail Council of Canada's Retail Marketing conference with leaders from Walmart & Google. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, CanWest Media, Pandora Jewellery, The Shopping Channel and Retail Council of Canada to his advisory, speaking and media practice.Michael produces and hosts a network of leading retail trade podcasts, including the award-winning No.1 independent retail industry podcast in America, Remarkable Retail with his partner, Dallas-based best-selling author Steve Dennis; Canada's top retail industry podcast The Voice of Retail and Canada's top food industry and one of the top Canadian-produced management independent podcasts in the country, The Food Professor with Dr. Sylvain Charlebois from Dalhousie University in Halifax.Rethink Retail has recognized Michael as one of the top global retail experts for the fourth year in a row, Thinkers 360 has named him on of the Top 50 global thought leaders in retail, RTIH has named him a top 100 global though leader in retail technology and Coresight Research has named Michael a Retail AI Influencer. If you are a BBQ fan, you can tune into Michael's cooking show, Last Request BBQ, on YouTube, Instagram, X and yes, TikTok.Michael is available for keynote presentations helping retailers, brands and retail industry insiders explaining the current state and future of the retail industry in North America and around the world.

Americans are currently besotted with protein. It's touted as being good for muscle growth, weight loss, skincare, mental acuity, longevity, and much else besides. It's sold to men, women, children, the elderly— you can even buy protein for your pets. The protein supplement market alone is worth $21 billion and growing—and extra protein is being added to coffee, cereal, pasta, beer, ice cream, and popcorn. But as frenzied as we currently are about protein, this is not the first protein boom—or even the second. Protein has been promoted as a charismatic, cure-all nutrient for nearly two centuries. In this episode, with the help of Samantha King and Gavin Weedon, the authors of Protein: The Making of a Nutritional Superstar, we look closely at all our protein crazes and their associated protein products—from beef tea to whey powder—and see what they can tell us about our current protein mania.  This episode was produced by Max Freedman. Decoder Ring is also produced by Willa Paskin, Katie Shepherd, and Evan Chung, our supervising producer. We had editing support from Josh Levin and fact-checking by Sophie Summergrad. Merritt Jacob is Senior Technical Director. If you have any cultural mysteries you want us to decode, email us at DecoderRing@slate.com  or leave a message on our hotline at (347) 460-7281. Get more of Decoder Ring with Slate Plus! Join for exclusive bonus episodes of Decoder Ring and ad-free listening on all your favorite Slate podcasts. Subscribe from the Decoder Ring show page on Apple Podcasts or Spotify. Or, visit slate.com/decoderplus for access wherever you listen. Sources for This Episode King, Samantha and Gavin Weedon. Protein: The Making of a Nutritional Superstar, Duke University Press, 2026. Baker, Ryan. “Protein has become America's latest obsession. Companies like General Mills and PepsiCo are capitalizing on it,” CNBC, July 22, 2025. Brock, William H. Justus von Liebig: The Chemical Gatekeeper, Cambridge University Press, 1997. Callahan, Alice. “The More Protein, the Better?” New York Times, April 9, 2025. Draper, Kevin. “America's Protein Obsession Is Transforming the Dairy Industry,” New York Times, July 16, 2025. Gayomali, Chris. “Big Food Gets Jacked: How protein mania took over the American grocery store,” New York Magazine, Feb. 12, 2025. “The Great Protein Fiasco,” Maintenance Phase, Aug. 31, 2021. Liebig, Justus von. Researches on the Chemistry of Food, Taylor and Walton, 1847. McLaren, Donald S. “The Great Protein Fiasco,” The Lancet, 1974. Oncken, John. “Stingy, 'half-way' dairy farmer's curiosity changed the world,” Wisconsin State Farmer, April 27, 2022. “Subject of Whey Disposal Discussed in UW Bulletin.” Wausau Daily Herald, Aug. 28, 1965. Torrella, Kenny. “You're probably eating way too much protein,” Vox, Jan. 30, 2024. Wilson, Bee. “Protein mania: the rich world's new diet obsession,” The Guardian, Jan. 4, 2019. Wu, Katherine J. “Should We All Be Eating Like The Rock?” The Atlantic, Aug. 28, 2023. Learn more about your ad choices. Visit megaphone.fm/adchoices

Americans are currently besotted with protein. It's touted as being good for muscle growth, weight loss, skincare, mental acuity, longevity, and much else besides. It's sold to men, women, children, the elderly— you can even buy protein for your pets. The protein supplement market alone is worth $21 billion and growing—and extra protein is being added to coffee, cereal, pasta, beer, ice cream, and popcorn. But as frenzied as we currently are about protein, this is not the first protein boom—or even the second. Protein has been promoted as a charismatic, cure-all nutrient for nearly two centuries. In this episode, with the help of Samantha King and Gavin Weedon, the authors of Protein: The Making of a Nutritional Superstar, we look closely at all our protein crazes and their associated protein products—from beef tea to whey powder—and see what they can tell us about our current protein mania.  This episode was produced by Max Freedman. Decoder Ring is also produced by Willa Paskin, Katie Shepherd, and Evan Chung, our supervising producer. We had editing support from Josh Levin and fact-checking by Sophie Summergrad. Merritt Jacob is Senior Technical Director. If you have any cultural mysteries you want us to decode, email us at DecoderRing@slate.com  or leave a message on our hotline at (347) 460-7281. Get more of Decoder Ring with Slate Plus! Join for exclusive bonus episodes of Decoder Ring and ad-free listening on all your favorite Slate podcasts. Subscribe from the Decoder Ring show page on Apple Podcasts or Spotify. Or, visit slate.com/decoderplus for access wherever you listen. Sources for This Episode King, Samantha and Gavin Weedon. Protein: The Making of a Nutritional Superstar, Duke University Press, 2026. Baker, Ryan. “Protein has become America's latest obsession. Companies like General Mills and PepsiCo are capitalizing on it,” CNBC, July 22, 2025. Brock, William H. Justus von Liebig: The Chemical Gatekeeper, Cambridge University Press, 1997. Callahan, Alice. “The More Protein, the Better?” New York Times, April 9, 2025. Draper, Kevin. “America's Protein Obsession Is Transforming the Dairy Industry,” New York Times, July 16, 2025. Gayomali, Chris. “Big Food Gets Jacked: How protein mania took over the American grocery store,” New York Magazine, Feb. 12, 2025. “The Great Protein Fiasco,” Maintenance Phase, Aug. 31, 2021. Liebig, Justus von. Researches on the Chemistry of Food, Taylor and Walton, 1847. McLaren, Donald S. “The Great Protein Fiasco,” The Lancet, 1974. Oncken, John. “Stingy, 'half-way' dairy farmer's curiosity changed the world,” Wisconsin State Farmer, April 27, 2022. “Subject of Whey Disposal Discussed in UW Bulletin.” Wausau Daily Herald, Aug. 28, 1965. Torrella, Kenny. “You're probably eating way too much protein,” Vox, Jan. 30, 2024. Wilson, Bee. “Protein mania: the rich world's new diet obsession,” The Guardian, Jan. 4, 2019. Wu, Katherine J. “Should We All Be Eating Like The Rock?” The Atlantic, Aug. 28, 2023. Learn more about your ad choices. Visit megaphone.fm/adchoices

Americans are currently besotted with protein. It's touted as being good for muscle growth, weight loss, skincare, mental acuity, longevity, and much else besides. It's sold to men, women, children, the elderly— you can even buy protein for your pets. The protein supplement market alone is worth $21 billion and growing—and extra protein is being added to coffee, cereal, pasta, beer, ice cream, and popcorn. But as frenzied as we currently are about protein, this is not the first protein boom—or even the second. Protein has been promoted as a charismatic, cure-all nutrient for nearly two centuries. In this episode, with the help of Samantha King and Gavin Weedon, the authors of Protein: The Making of a Nutritional Superstar, we look closely at all our protein crazes and their associated protein products—from beef tea to whey powder—and see what they can tell us about our current protein mania.  This episode was produced by Max Freedman. Decoder Ring is also produced by Willa Paskin, Katie Shepherd, and Evan Chung, our supervising producer. We had editing support from Josh Levin and fact-checking by Sophie Summergrad. Merritt Jacob is Senior Technical Director. If you have any cultural mysteries you want us to decode, email us at DecoderRing@slate.com  or leave a message on our hotline at (347) 460-7281. Get more of Decoder Ring with Slate Plus! Join for exclusive bonus episodes of Decoder Ring and ad-free listening on all your favorite Slate podcasts. Subscribe from the Decoder Ring show page on Apple Podcasts or Spotify. Or, visit slate.com/decoderplus for access wherever you listen. Sources for This Episode King, Samantha and Gavin Weedon. Protein: The Making of a Nutritional Superstar, Duke University Press, 2026. Baker, Ryan. “Protein has become America's latest obsession. Companies like General Mills and PepsiCo are capitalizing on it,” CNBC, July 22, 2025. Brock, William H. Justus von Liebig: The Chemical Gatekeeper, Cambridge University Press, 1997. Callahan, Alice. “The More Protein, the Better?” New York Times, April 9, 2025. Draper, Kevin. “America's Protein Obsession Is Transforming the Dairy Industry,” New York Times, July 16, 2025. Gayomali, Chris. “Big Food Gets Jacked: How protein mania took over the American grocery store,” New York Magazine, Feb. 12, 2025. “The Great Protein Fiasco,” Maintenance Phase, Aug. 31, 2021. Liebig, Justus von. Researches on the Chemistry of Food, Taylor and Walton, 1847. McLaren, Donald S. “The Great Protein Fiasco,” The Lancet, 1974. Oncken, John. “Stingy, 'half-way' dairy farmer's curiosity changed the world,” Wisconsin State Farmer, April 27, 2022. “Subject of Whey Disposal Discussed in UW Bulletin.” Wausau Daily Herald, Aug. 28, 1965. Torrella, Kenny. “You're probably eating way too much protein,” Vox, Jan. 30, 2024. Wilson, Bee. “Protein mania: the rich world's new diet obsession,” The Guardian, Jan. 4, 2019. Wu, Katherine J. “Should We All Be Eating Like The Rock?” The Atlantic, Aug. 28, 2023. Learn more about your ad choices. Visit megaphone.fm/adchoices

Americans are currently besotted with protein. It's touted as being good for muscle growth, weight loss, skincare, mental acuity, longevity, and much else besides. It's sold to men, women, children, the elderly— you can even buy protein for your pets. The protein supplement market alone is worth $21 billion and growing—and extra protein is being added to coffee, cereal, pasta, beer, ice cream, and popcorn. But as frenzied as we currently are about protein, this is not the first protein boom—or even the second. Protein has been promoted as a charismatic, cure-all nutrient for nearly two centuries. In this episode, with the help of Samantha King and Gavin Weedon, the authors of Protein: The Making of a Nutritional Superstar, we look closely at all our protein crazes and their associated protein products—from beef tea to whey powder—and see what they can tell us about our current protein mania.  This episode was produced by Max Freedman. Decoder Ring is also produced by Willa Paskin, Katie Shepherd, and Evan Chung, our supervising producer. We had editing support from Josh Levin and fact-checking by Sophie Summergrad. Merritt Jacob is Senior Technical Director. If you have any cultural mysteries you want us to decode, email us at DecoderRing@slate.com  or leave a message on our hotline at (347) 460-7281. Get more of Decoder Ring with Slate Plus! Join for exclusive bonus episodes of Decoder Ring and ad-free listening on all your favorite Slate podcasts. Subscribe from the Decoder Ring show page on Apple Podcasts or Spotify. Or, visit slate.com/decoderplus for access wherever you listen. Sources for This Episode King, Samantha and Gavin Weedon. Protein: The Making of a Nutritional Superstar, Duke University Press, 2026. Baker, Ryan. “Protein has become America's latest obsession. Companies like General Mills and PepsiCo are capitalizing on it,” CNBC, July 22, 2025. Brock, William H. Justus von Liebig: The Chemical Gatekeeper, Cambridge University Press, 1997. Callahan, Alice. “The More Protein, the Better?” New York Times, April 9, 2025. Draper, Kevin. “America's Protein Obsession Is Transforming the Dairy Industry,” New York Times, July 16, 2025. Gayomali, Chris. “Big Food Gets Jacked: How protein mania took over the American grocery store,” New York Magazine, Feb. 12, 2025. “The Great Protein Fiasco,” Maintenance Phase, Aug. 31, 2021. Liebig, Justus von. Researches on the Chemistry of Food, Taylor and Walton, 1847. McLaren, Donald S. “The Great Protein Fiasco,” The Lancet, 1974. Oncken, John. “Stingy, 'half-way' dairy farmer's curiosity changed the world,” Wisconsin State Farmer, April 27, 2022. “Subject of Whey Disposal Discussed in UW Bulletin.” Wausau Daily Herald, Aug. 28, 1965. Torrella, Kenny. “You're probably eating way too much protein,” Vox, Jan. 30, 2024. Wilson, Bee. “Protein mania: the rich world's new diet obsession,” The Guardian, Jan. 4, 2019. Wu, Katherine J. “Should We All Be Eating Like The Rock?” The Atlantic, Aug. 28, 2023. Learn more about your ad choices. Visit megaphone.fm/adchoices

Links mentioned ⬇️Lancet 2024 risk factor PDFMy Alzheimer's risk episode⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯Where to find Barbie ⬇️InstagramSubstack⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯Where to find me ⬇️InstagramPodcast⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯My group program ⬇️WOMP Training [Gym + Home]⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯Helping you find the balance between OPTIMAL and PRACTICAL

https://www.tadeclinicagem.com.br/guia/?utm_source=whatsapp&utm_medium=social&utm_term=&utm_content=&utm_campaign=Guia-blackfriday&utm_source_platform=&utm_creative_format=&utm_marketing_tactic=

Ultra-processed foods are becoming so dominant in our diets, they are causing a surge in diabetes, obesity, heart disease, and depression, that's according to research that has just been released this afternoon. The findings are in three papers by a group of scientists from around the world, including one from New Zealand and published in the medical journal, The Lancet. It's estimated that consumption of ultra processed food here in New Zealand is around 50-60 percent of our diet. The New Zealander who co-authored one of The Lancet papers is Auckland University Professor Boyd Swinburn. He talks to Jesse.

Dans cette édition :Le gouvernement français s'engage dans une lutte à mort contre le narcotrafic, avec des opérations de police comme PlaceNet qui peinent à endiguer le phénomène à Marseille.À Strasbourg, un candidat d'extrême-gauche fait polémique en distribuant ses tracts de campagne en plusieurs langues, suscitant des critiques sur la langue de la République.Au Royaume-Uni, le gouvernement durcit sa politique migratoire face à l'augmentation du nombre de migrants illégaux, transformant certains quartiers de Londres.Une étude publiée dans The Lancet alerte sur les dangers pour la santé de la consommation d'aliments ultra-transformés, qui représentent 35% des apports caloriques en France.Le budget 2023 fait débat à l'Assemblée nationale, avec un risque de non-adoption du texte, obligeant le gouvernement à envisager des solutions de repli.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Tonight, on The Panel, Wallace Chapman is joined by panellists Denise L'Estrange Corbet and Peter Field. First up, ultra processed food has been linked to harm in every major organ system of the human body. That's according to the world's largest review just published in The Lancet. In New Zealand how is our food policy? is it protecting us from UPFs? Then, the Supreme Court ruled on Monday that four Uber drivers were employees in a test case, entitling them to benefits such as sick leave, holiday pay and a minimum wage. A win for them, but does this have any implications for future cases?

A new Lancet report has found that eating excessive ultra processed foods is leading to increased risk of chronic diseases. They are calling for a global response to put pressure on the production of processed foods, and improve access to healthier alternatives. How bad are these foods for us, and what can we do to avoid the worst of them?Joining me now to discuss is Consultant Endocrinologist and HSE National Clinical Lead for Obesity Donal O'Shea, Dietician and Founder of Eatwell Sarah Keogh and Gerry Devlin, Chef & owner of Dublin Cookery School.

Dans cette édition :Le gouvernement français s'engage dans une lutte à mort contre le narcotrafic, avec des opérations de police comme PlaceNet qui peinent à endiguer le phénomène à Marseille.À Strasbourg, un candidat d'extrême-gauche fait polémique en distribuant ses tracts de campagne en plusieurs langues, suscitant des critiques sur la langue de la République.Au Royaume-Uni, le gouvernement durcit sa politique migratoire face à l'augmentation du nombre de migrants illégaux, transformant certains quartiers de Londres.Une étude publiée dans The Lancet alerte sur les dangers pour la santé de la consommation d'aliments ultra-transformés, qui représentent 35% des apports caloriques en France.Le budget 2023 fait débat à l'Assemblée nationale, avec un risque de non-adoption du texte, obligeant le gouvernement à envisager des solutions de repli.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

El consumo de ultraprocesados se ha triplicado. Son rápidos de consumir, atractivos y generalmente baratos —no han subido tanto en la cesta de la compra como los alimentos frescos—. Pero pese a la diferencia de precios, el riesgo es muy grande: perjudican nuestra salud y engañan a nuestro cerebro. ¿Por qué no podemos dejar de comer ultraprocesados? Lo analizamos con Pilar Pérez, jefa de la sección de Salud de EL MUNDOSee omnystudio.com/listener for privacy information.

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-459 Overview: Cognitive decline risk may be reduced through modifiable lifestyle factors, creating an opportunity for early intervention in primary care. Join us as we review findings from the US POINTER trial, which evaluated the impact of structured vs. self-guided lifestyle interventions on the risk of cognitive decline in older adults. Come away with tips to apply this evidence in real-world scenarios with your patients. Episode resource links: Baker LD, Espeland MA, Whitmer RA, et al. Structured vs self-guided multidomain lifestyle interventions for global cognitive function: The US POINTER randomized clinical trial. JAMA. 2025;334(8):681-691. doi:10.1001/jama.2025.12923 Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10421):572-628. doi:10.1016/S0140-6736(24)01296-0 Guest: Jillian Joseph, MPAS, PA-C Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com   

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-459 Overview: Cognitive decline risk may be reduced through modifiable lifestyle factors, creating an opportunity for early intervention in primary care. Join us as we review findings from the US POINTER trial, which evaluated the impact of structured vs. self-guided lifestyle interventions on the risk of cognitive decline in older adults. Come away with tips to apply this evidence in real-world scenarios with your patients. Episode resource links: Baker LD, Espeland MA, Whitmer RA, et al. Structured vs self-guided multidomain lifestyle interventions for global cognitive function: The US POINTER randomized clinical trial. JAMA. 2025;334(8):681-691. doi:10.1001/jama.2025.12923 Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10421):572-628. doi:10.1016/S0140-6736(24)01296-0 Guest: Jillian Joseph, MPAS, PA-C Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com   

Poudre dans un shaker. Blanc de poulet grillé. Gros biceps.

Send us a textRecently, a trend has captured public attention: female athletes have been beating the strongest male contenders, in the toughest races in the world, races designed for men. In Ultra Women, the authors (who are themselves endurance athletes) delve into the surprising science of sporting performance to explore the physiological and psychological differences between the sexes. They ask: could fat stores and muscle type (and capacity for not sleeping) really give women an edge over men in ultra long distances? And what roles are played by pace, preparation, and motherhood? Speaking to elite athletes, historians and scientists, the book unearths the largely unknown past of female endurance, from hunter- gathering to the early 20th Century discipline of pedestrianism and we get to meet some amazing women who have done amazing things.These bios are not going to do justice to these two women because they do a lot more than we could cover in the number of characters allowed in this description, but here it goes! Lily Canter is a freelance running, fitness and  adventure travel journalist writing for Runner's  World, Live for the Outdoors, Women's Health,  The Guardian and Metro. She is an England  Athletics running coach and founder of  women's only club Great Bowden Runners. She  competes in ultra marathons and canicrosses  with her dog. Instagram: @lilycanter Emma Wilkinson is an award-winning  freelance journalist specialising in medicine,  science and health. She has written for the  Sunday Times, BBC, Pulse, the BMJ and Lancet  among others. Emma lives in Sheffield and runs  up hills for fun. Instagram: @emmawjourno If you're interested in getting a copy of this book for yourself then you can find it on Amazon or directly on the publishers website here: https://www.canburypress.com/products/presale-ultra-women-by-lily-canter-and-emma-wilkinson-isbn-9781914487101?srsltid=AfmBOopm-PGhLV9ZE2vjNfl-wobGtYreNsxyJ2F_VNPUtgLWH1VGzlsyLink for 20% discount on Caffeine Bullet https://caffeinebullet.com/RUNNINGBOOK Discount automatically applied and visible on checkoutSupport the showAny feedback or suggestions on this review or any of our other podcast episodes would be greatly welcomed. Leave us a review using your favorite podcast player or contact us on social media. Facebook: https://www.facebook.com/runningbookreviews/Twitter: https://twitter.com/reviews_runningInstagram: https://www.instagram.com/runningbookreviews/ Podcast webpage: https://runningbookreviews.buzzsprout.com If you have been enjoying the podcast and want more, you can find some extras on our By Me a Coffee site! https://www.buymeacoffee.com/runningbookreviews

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: It's World Diabetes Day and we have a LOT of news to get to! Daily oral insulin tested to prevent T1D, mothers and sons and a T1D link, stem cell updates, Tandem Android news, Omnipod's workplace campaign and more! Find out how to submit your Community Commercial Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. It's world diabetes day! It is marked every year on 14 November, the birthday of Sir Frederick Banting, who co-discovered insulin along with Charles Best in 1922.   WDD was created in 1991 by International Diabetes Federation (IDF) and the World Health Organization and became an official United Nations Day in 2006 with the passage of United Nations Resolution 61/225. There will be a ton of stuff in your feeds today and that's great! I'm going to keep this to a pretty normal in the news episode.. although I do have my own World Diabetes Day announcement – I want YOUR community commercials. You could have an ad for your event or your blog or your project right here! There's a post on the website explaining it all and I'll come back at the end of the episode and tell you more. XX The Primary Oral Insulin Trial (POInT) is the first large-scale clinical trial to test whether giving at-risk children daily oral insulin could prevent or delay type 1 diabetes (T1D). Conducted by researchers from Helmholtz Munich and the Technical University of Munich across five European countries, the study enrolled more than 1,000 children with a genetic risk for T1D. Results published in The Lancet show that while oral insulin did not prevent the development of islet autoantibodies—an early sign of diabetes—it was safe and well tolerated. Importantly, researchers found that some children who received oral insulin developed diabetes more slowly than those given a placebo, suggesting potential protective effects in certain genetic subgroups.   Further analysis revealed that the response to treatment depended on the child's insulin gene variant. Children with genetic versions that raise diabetes risk appeared to benefit, showing delayed onset of the disease, while those without the risk variant did not. These findings point toward a future of personalized prevention, where genetic screening could help identify which children might benefit most from oral insulin. Researchers will continue following the participants until age 12 to assess long-term effects. The study marks a major milestone in decades of diabetes prevention research, highlighting both the promise and complexity of developing tailored, early interventions against type 1 diabetes. XX Joint US-Chinese research looking at generating new beta cells from stomach cells. Upon turning on the "genetic switch," the human stomach cells were converted to insulin-secreting cells within the mice and resembled pancreatic beta cells with respect to gene and protein expression. Encouragingly, when those experiments were done with diabetic mice, insulin secreted from the transformed human cells helped control blood sugar levels and ameliorated diabetes. The scientists hope that a similar approach can be taken to convert cells from a patient's own stomach into insulin-secreting cells directly within the body. Importantly, additional studies are needed to address if this approach is safe and effective to be used in patients. https://www.technologynetworks.com/cell-science/news/human-stomach-cells-tweaked-to-make-insulin-406694 XX A new study in Nature Metabolism may help explain why children born to mothers with type 1 diabetes are less likely to develop the disease early in life compared to those whose fathers or siblings have it. Researchers looked at nearly 2,000 mothers and their children and found that  kids whose moms have type 1 diabetes show changes in their DNA that may actually help protect them. These aren't genetic mutations, but epigenetic changes — chemical tags that turn certain genes on or off. The study found these changes in genes tied to the immune system and type 1 diabetes risk, suggesting that a mother's condition during pregnancy can shape her child's immune response in a protective way. Scientists identified more than 500 areas of DNA where these changes occurred, many in regions that control how the body's immune system works. Most of the changes appeared to calm down the kind of overactive immune response that leads to type 1 diabetes. Researchers even created a "methylation score" to help measure this protective effect. They say the next step is to confirm these results in more diverse groups and figure out exactly how these DNA changes help prevent early diabetes. https://www.news-medical.net/news/20251110/Maternal-type-1-diabetes-may-protect-children-from-developing-the-disease.aspx XX A new study from Karolinska Institutet and Stockholm University reveals that sons born to mothers with type 1 diabetes may develop early vascular dysfunction—independently of metabolic health. The finding may help shape future strategies to prevent cardiovascular disease early in life.     Children of women with type 1 diabetes are known to be at increased risk of developing cardiovascular diseases. This new study, published in Cell Reports Medicine, is the first to show that the risk is linked to early dysfunction in blood vessel cells in sons, even before any metabolic issues arise. The team is now investigating the long-term effects of maternal diabetes, with a particular focus on why sons seem to be affected earlier than daughters. https://medicalxpress.com/news/2025-11-sons-mothers-diabetes-early-vascular.html XX A new study presented at Kidney Week 2025 has shown that the drug finn-uh-near-own  a nonsteroidal mineralocorticoid-receptor antagonist, significantly reduced albuminuria—a key marker of kidney damage—in people with type 1 diabetes (T1D) and chronic kidney disease (CKD). This is the first major breakthrough for this population in more than 30 years. Researchers found that patients taking finerenone saw a 25% average reduction in albuminuria compared to placebo, an improvement that suggests a lower long-term risk for dialysis or kidney transplant. The phase 3 FINE-ONE trial involved 242 adults with T1D and CKD, and results showed benefits as early as three months. The drug was generally well tolerated, with side effects similar to those seen in patients with type 2 diabetes, though mild hyperkalemia (high potassium levels) was slightly more common. Experts say the findings could change the way doctors treat kidney complications in type 1 diabetes, an area that hasn't seen new therapies since the early 1990s. Currently, treatment options rely on blood pressure and blood sugar management, along with renin-angiotensin system (RAS) inhibitors. Finerenone, which is already approved for type 2 diabetes-related CKD, targets overactivation of a receptor that drives kidney damage. Based on these results, Bayer plans to seek FDA approval in 2026 for use in people with T1D and CKD. Researchers and clinicians alike are calling the study "groundbreaking," noting that it opens the door to future research on how finerenone might not just slow kidney decline—but possibly prevent it altogether. https://www.medscape.com/viewarticle/finerenone-offers-hope-kidney-disease-type-1-diabetes-2025a1000uzi?form=login   XX This week, Tandem Diabetes Care (Nasdaq:TNDM) announced a major milestone for its Mobi miniature durable insulin pump system. San Diego-based Tandem revealed that it received FDA approval for the Android version of its Mobi mobile app. Clearance brings Mobi — which the company describes as the world's smallest, durable automated insulin delivery system — to more users. The pump, which pairs with Tandem's Control-IQ+ algorithm, previously worked with iOS software.   Tandem — one of the largest diabetes tech companies in the world — expects to begin a limited rollout next month, followed by full commercial availability in early 2026. This marks the latest milestone for the company, which continues to expand its offerings and widen its reach within the diabetes patient population.   We had a great interview with Tandem on our previous episode, but as I said at the time, it was coming before their earnings call. So here's an update: The company plans to submit the tubeless mobi to the fda before the end of this year.. possible approval and shipping date is hoped for by middle of 2026. Trials for their fully closed loop next-generation algorithm which we tlkaed abou ton the show should be launched in 2026 The Sigi patch pump will be developed and launched as a next-generation version of the Mobi Great job by Dr. David ? Ahn – he posted on IG after getting a message from tandem CEO John Sheridan? 1. First, the Tandem X3 *is* still absolutely in development, contrary to my speculation In yesterday's video. As many of you appropriately pointed out, there is definitely a market for a 300 unit pump, a pump with a screen, and a pump that does not require smartphone control. So from our brief chat, the sense I got that is that the X3 would be more of a refresh of the X2 with newer components, such as a USB-C connector and better memory, rather than a total redesign from the ground up. In terms of timing, all I could get was that it was "not too far distant in the future," which could mean anything I guess, but at least it's still on the way! 2. Next up, he also reassured me that they are working closely with Dexcom to support the G7 15 Day sensor within the next few months. I suspected as much, but it's always good to hear confirmation. 3. Lastly, he did confirm that Tandem is far along in developing a Caregiver/Follow app to allow the remote viewing of glucose and insulin data from a Tandem pump. He explained that it will be based on Sugarmate, the popular diabetes data dashboard app that Tandem acquired back in Jun 2020. While I don't know if every feature will make it into the Tandem caregiver app, Sugarmate is well-liked for its highly customizable dashboard and highly configurable alerts. Sugarmate even has the option to send a text message or phone call for urgent lows. Regardless, a true follow/Caregiver app will be welcomed with open arms by all caregivers and Tandem users who use Libre 3 Plus. https://time.com/7318020/worlds-top-healthtech-companies-2025/ XX Senseonics submits Eversense 365 – their year long implantable CGM for a CE mark, European Approval and expect to launch there soon. Eversense will be integrated with the sequel twist pump – again I'm hearing soon but no timeline. Intersting to note that one year inseration was approved in the US just about a year ago, so the first patients will be having their CGMs changed out – for the first time – pretty soon. https://www.drugdeliverybusiness.com/senseonics-q2-2025-sales-beat-ce-mark/ XX A confusing study out of Rutgers - these researcher say  metformin reduces some of the key benefits normally gained from regular physical activity. These include improvements in blood vessel health, physical fitness, and the body's ability to regulate blood sugar. Since 2006, doctors have typically encouraged patients with elevated blood sugar levels to combine metformin with exercise, expecting that the two proven treatments would produce stronger results together. However, the new research suggests this may not be the case. In this study, Exercise alone improved vascular insulin sensitivity, meaning blood vessels responded better to insulin and allowed more blood flow to muscles. This matters because insulin's ability to open blood vessels helps shuttle glucose out of the bloodstream and into tissues, lowering blood sugar after meals. But when metformin was added, the improvements shrank. The drug also diminished gains in aerobic fitness and reduced the positive effects on inflammation and fasting glucose. The findings don't mean people should stop taking metformin or exercising, Malin said. Instead, it raises urgent questions for doctors about how the two treatments can be combined and the need for close monitoring. Malin hopes future research will uncover strategies that preserve the benefits of both. https://scitechdaily.com/popular-diabetes-drug-metformin-may-cancel-out-exercise-benefits-study-warns/ XX XX https://www.medtechdive.com/news/Revvity-Sanofi-diabetes-test-Kihealth-seed-round/802133/   XX Dexcom recalled an Android app for its G6 glucose sensor due to a software problem that could cause the app to terminate unexpectedly. The issue could cause users to miss alarms, alerts or notifications related to estimated glucose values, according to a Food and Drug Administration database entry posted Oct. 30. The glucose sensor and the app are still available, but Dexcom required users to update the app to a new version. Dexcom began the recall on Aug. 28. The FDA designated the event as a Class 1 recall, the most serious kind. Dexcom sent a notification to customers in September about the software bug, which applies to version 1.15 of the G6 Android app. To use the app, customers must update it to a new version, according to the entry. https://www.medtechdive.com/news/dexcom-recall-g6-cgm-app/804630/ XX https://www.medscape.com/viewarticle/automated-insulin-delivery-boosts-glycemic-control-youth-2025a1000ub3 XX Tidepool partners with smart ring maker OURA.. press release says: to support a groundbreaking dataset intended to be broadly available for diabetes research, with participation limited to individuals who opt in through Tidepool.         Tidepool will pair biometric data from Oura Ring – sleep, activity, heart rate, temperature trends, and menstrual cycles – with diabetes device data, including continuous glucose monitors (CGMs) and insulin pumps. The result will provide researchers with an unprecedented dataset to accelerate the development of new clinical guidelines, next-generation diabetes technology, and personalized care models.   Recruitment is expected to launch in early 2026 through an IRB-approved study. By opting in to this study, participants consent to sharing their data with Tidepool's Big Data Donation Project, where data is de-identified and, with participant consent, shared with academics, researchers, and industry innovators to accelerate diabetes research. https://aijourn.com/tidepool-collaborates-with-oura-to-advance-inclusive-diabetes-research-through-wearables/ XX Eli Lilly launches two new clinical trials for baricitinib. These phase 3 trials will investigate whether the drug can delay T1D onset or progression and will open for recruitment soon. Baricitinib has the potential to extend the "honeymoon period" of T1D, meaning that it could preserve remaining insulin-producing beta cells earlier in disease progression. More beta cells mean better blood sugar management—and potentially reduced long-term complications. JAK inhibitors, including baricitinib, are already FDA-approved for other autoimmune diseases, such as rheumatoid arthritis, alopecia, and more. JAK signaling pathways are associated with overactive immune responses, so blocking this pathway may turn down the immune response. The phase 2 Breakthrough T1D-funded BANDIT study was key in showing that this drug is safe and effective in T1D. Importantly, baricitinib is a once-daily oral pill—meaning its use is simple and easy.   https://www.breakthrought1d.org/news-and-updates/two-new-trials-baricitinib-to-delay-t1d/ XX   Insulet is taking diabetes awareness into the workplace. Having found 79% of people with diabetes have faced bias or misunderstanding at work, the medtech giant is rolling out a range of resources intended to trigger changes in how workplaces approach the condition. Lots going on for Diabetes Awareness month.. some notables.. Insulet's "The Day Diabetes Showed up to Work" campaign. based on a survey of almost 10,000 people 79% of people with diabetes have faced bias or misunderstanding at work,.   Almost 90% of people with diabetes surveyed reported experiencing barriers at work due to their condition, and more than 40% of people with diabetes and caregivers said they have workplace-related anxiety tied to the metabolic disease. Around one-quarter of respondents reported fears that diabetes could limit opportunities or lead to workplace discrimination and judgment, and a similar proportion of people said they conceal their condition. https://www.fiercepharma.com/marketing/widespread-workplace-challenges-people-diabetes-spark-insulet-campaign XX New directive issued by the Trump administration could mean people seeking visas to live in the U.S. might be rejected if they have certain medical conditions, including diabetes or obesity.   The guidance, issued in a cable the State Department sent to embassy and consular officials and examined by KFF Health News, directs visa officers to deem applicants ineligible to enter the U.S. for several new reasons, including age or the likelihood they might rely on public benefits.   The guidance says that such people could become a "public charge" — a potential drain on U.S. resources — because of their health issues or age.   The cable's language appears at odds with the Foreign Affairs Manual, the State Department's own handbook, which says that visa officers cannot reject an application based on "what if" scenarios, Wheeler said.   The guidance directs visa officers to develop "their own thoughts about what could lead to some sort of medical emergency or sort of medical costs in the future," he said. "That's troubling because they're not medically trained, they have no experience in this area, and they shouldn't be making projections based on their own personal knowledge or bias."   Immigrants already undergo a medical exam by a physician who's been approved by a U.S. embassy. https://www.npr.org/2025/11/12/nx-s1-5606348/immigrants-visas-health-conditions-trump-guidance XX SAN DIEGO---Nov. 14, 2025—DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of Dexcom's World Diabetes Day campaign. The advocates – ranging from ages six to 68, spanning various types of diabetes, and hailing from four continents and five countries – were selected from 1,000 open call submissions based on their experiences advocating for people with diabetes in their communities. While each person's experience with diabetes is unique, they share a common passion for advocacy – and use of Dexcom's glucose biosensing technology. "Through advocacy, I strive to show others, especially children and newly diagnosed patients, that diabetes is not a limitation but an opportunity to grow stronger, inspire resilience and pursue ambitious goals," said Maria Alejandra Jove Valerio, one of Dexcom's new advocates. "What began as a diagnosis at age seven has grown into a lifelong mission to uplift others." This effort represents the first time Dexcom has sourced voices from the broader diabetes community specifically for its World Diabetes Day campaign, reinforcing Dexcom's history of and commitment to giving real people with diabetes a platform to share their story on a global stage. Through engaging, editorial-style portraits and deeply personal stories, the campaign highlights each advocate's personal experience with diabetes, what misconceptions about diabetes they'd like to dispel and how they want to inspire others with diabetes to discover what they're made of. To prepare for the spotlight, the group of advocates met in Los Angeles for a World Diabetes Day photoshoot which included a surprise visit from Grammy-nominated artist, actor, producer and Dexcom Warrior Lance Bass and author, producer, actress and Stelo*Ambassador Retta. This visit offered the advocates an opportunity to exchange stories and personal perspectives on the meaning of diabetes advocacy and how they live it each day. Behind the lens at the shoot was another member of the diabetes community—photographer Tommy Lundberg who lives with Type 1 diabetes. "Directing this photoshoot was nothing short of inspiring. Each of these advocates has a unique an XX On what would have been the 100th birthday of its visionary founder Alfred E. Mann, MannKind Corporation (Nasdaq: MNKD), in partnership with Alfred E. Mann Charities and The Diabetes Link, announced the launch of the Centennial Al Mann Scholarship. The new program will distribute $100,000 in scholarship funds to support at least 10 young adult students living with diabetes as they pursue higher education in life sciences.   Launched in Diabetes Awareness Month, the scholarship program honors Alfred E. Mann's enduring legacy of innovation, philanthropy, and his lifelong commitment to improving the quality of human life through medical advancement. Deeply passionate about giving back, Mr. Mann believed that his success should continue to serve humanity long after his passing, a belief that lives on through this initiative.   Each scholarship recipient will be awarded up to $10,000, distributed in annual installments of $2,500 throughout the course of their studies. Depending on the length of their degree program, recipients may receive between two and four installments (up to the full $10,000 per student). The first awards will be made for the 2026 academic year.   "Al Mann dedicated his life to helping people with serious medical conditions live longer, healthier lives. This scholarship is a reflection of that spirit," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "By supporting students living with diabetes who are pursuing careers in the life sciences and adjacent fields, we're honoring Al's legacy and investing in the future of innovation and care. This program is about giving back to the community we serve and empowering the next generation to carry forward Al's mission of making a meaningful difference in people's lives."   Alfred E. Mann Charities and MannKind will partner with The Diabetes Link to launch the program to serve young adults (aged 18-22) living with either type 1 or type 2 diabetes with their higher education goals. Those eligible will include incoming freshmen and current students pursuing 2- or 4-year degrees. The application window will open in early 2026, and for those interested in receiving notifications, an early interest form is available. More information about the scholarship will be shared on thediabeteslink.org.   "We're honored to partner with MannKind to expand access to higher education for young adults with diabetes," said Manuel Hernández, Chief Executive Officer of The Diabetes Link. "At a time when the cost of college continues to rise, this scholarship helps ease the financial burden and carries forward the spirit of Al Mann, whose vision and legacy continue to inspire us."   Mr. Mann was MannKind's Chairman of the Board from 2001 until his passing in February 2016 and served as Chief Executive Officer from November 2003 until January 2015. Driven by a desire to improve lives and fill unmet medical needs, for more than six decades he founded 17 companies and developed breakthrough medical devices, including insulin pumps, cochlear implants, cardiac pacemakers and retinal prostheses. In 1997, Mr. Mann saw the potential of a dry powder insulin formulation to change the way diabetes is treated and invested nearly $1 billion to help bring Afrezza® (insulin human) Inhalation Powder to market.   About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.   With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.   Learn more at mannkindcorp.com.   About Alfred E. Mann Charities, Inc. Alfred E. Mann Charities, Inc. became active in 2016, following the passing of the organization's benefactor, Alfred E. Mann. Throughout his life, Al was passionate about philanthropy and was dedicated to prolonging and improving the quality of human lives through innovation in the fields of healthcare and the use of medical devices. It was important to Al that his success and assets continue to better human lives even after his own passing.   Alfred E. Mann Charities, Inc. (formerly known as Alfred E. Mann Family Foundation) has similarly placed its primary focus on healthcare and medical innovation, as our organization believes this is where we can have the greatest impact on humanity and human health throughout the world. Alfred E. Mann Charities, Inc. is also dedicated to promoting arts, culture, education, and community development across Los Angeles and throughout the world in order to best serve people and this planet.   Learn more at aemanncharities.org.   About The Diabetes Link The Diabetes Link is the only national nonprofit organization dedicated to empowering young adults living with diabetes. Founded by and for young adults, The Link serves this community through peer support, leadership opportunities, and practical, evidence-based resources designed for real life. Its network of campus and community chapters, active online community, and robust Resource Hub help young adults navigate the transitions of early adulthood while managing diabetes. The organization envisions a future where every young adult living with diabetes has

In this episode of MyHeart.net, cardiologist Dr. Alan Bouchard sits down with Dr. Timothy Garvey, Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham, to discuss the evolving definition of obesity as a disease. Drawing from The Lancet's 2025 clinical framework, Dr. Garvey explains when excess adiposity begins to impair organ function, how this redefinition changes patient care, and why understanding obesity as a chronic disease is essential for preventing cardiometabolic complications.About the TeamDr. Alain Bouchard is a clinical cardiologist at Cardiology Specialists of Birmingham, AL. He is a native of Quebec, Canada and trained in Internal Medicine at McGill University in Montreal. He continued as a Research Fellow at the Montreal Heart Institute. He did a clinical cardiology fellowship at the University of California in San Francisco. He joined the faculty at the University of Alabama Birmingham from 1986 to 1990. He worked at CardiologyPC and Baptist Medical Center at Princeton from 1990-2019. He is now part of the Cardiology Specialists of Birmingham at UAB Medicine.Dr. Philip Johnson is originally from Selma, AL. Philip began his studies at Vanderbilt University in Nashville, TN, where he double majored in Biomedical and Electrical Engineering. After a year in the “real world” working for his father as a machine design engineer, he went to graduate school at UAB in Birmingham, AL, where he completed a Masters and PhD in Biomedical Engineering before becoming a research assistant professor in Biomedical Engineering. After a short stint in academics, he continued his education at UAB in Medical School, Internal Medicine Residency, and is currently a cardiology fellow in training with a special interest in cardiac electrophysiology.Medical DisclaimerThe contents of the MyHeart.net podcast, including as textual content, graphical content, images, and any other content contained in the Podcast (“Content”) are purely for informational purposes. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read or heard on the Podcast!If you think you may have a medical emergency, call your doctor or 911 immediately. MyHeart.net does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the Podcast. Reliance on any information provided by MyHeart.net, MyHeart.net employees, others appearing on the Podcast at the invitation of MyHeart.net, or other visitors to the Podcast is solely at your own risk.The Podcast and the Content are provided on an “as is” basis.

Carotid artery disease management has come a long way. From the days when every stroke meant an endarterectomy to a modern era defined by precision, evidence, and evolving technology. With advances in medical therapy and newer techniques like TCAR, the vascular surgeon has even more to consider when choosing the best treatment for carotid disease. Join us as we break down the major landmark trials NASCET, CREST and the Asymptomatic Carotid trials, and discuss how their findings shape our clinical decisions in practice today. Hosts: ·      Christian Hadeed -PGY 4 General Surgery, Brookdale Hospital Medical Center ·      Paul Haser -Division Chief, Vascular Surgery, Brookdale Hospital Medical Center ·      Andrew Harrington, Vascular surgery, Brookdale Hospital Medical Center ·      Lucio Flores, Vascular surgery, Brookdale Hospital Medical Center Learning Objectives: · Review the key findings and clinical implications of the NASCET, ACST, and CREST trials. · Discuss patient selection for carotid endarterectomy (CEA) vs carotid artery stenting (CAS). · Understand how age, calcification, and aortic arch anatomy affect stenting outcomes or choice between stent and CEA. · Identify how advances in medical therapy have influenced management of asymptomatic disease.  · Discuss appropriate screening/ follow up plans for patients who do not meet criteria for intervention References: -       North American Symptomatic Carotid Endarterectomy Trial Collaborators. (1991). Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. The New England Journal of Medicine, 325(7), 445–453. https://pubmed.ncbi.nlm.nih.gov/1852179/ -       Brott, T. G., Hobson, R. W. II, Howard, G., Roubin, G. S., Clark, W. M., Brooks, W., ... & Howard, V. J. (2010). Stenting versus endarterectomy for treatment of carotid-artery stenosis. The New England Journal of Medicine, 363(1), 11–23. https://pubmed.ncbi.nlm.nih.gov/20505173/ -       Halliday, A., Mansfield, A., Marro, J., Peto, C., Peto, R., Potter, J., & Thomas, D.; MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. (2004). Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: Randomized controlled trial. The Lancet, 363(9420), 1491–1502. https://pubmed.ncbi.nlm.nih.gov/15135594/ -       Halliday, A., Bulbulia, R., Bonati, L. H., Chester, J., Cradduck-Bamford, A., Peto, R., & Pan, H., & the ACST-2 Collaborative Group. (2021). Second asymptomatic carotid surgery trial (ACST-2): A randomised comparison of carotid artery stenting versus carotid endarterectomy. The Lancet, 398(10305), 1065-1073. https://doi.org/10.1016/S0140-6736(21)01910-3 Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

In this solo episode, Darin reframes one of the most misunderstood forces in life — stress. Instead of seeing it as the enemy, he explores how stress is actually a messenger, guiding you back to alignment, safety, and awareness. Through science, spirituality, and lived experience, Darin breaks down how stress shows us where we're trying to control, where we're disconnected, and where our nervous system is calling for attention. He unpacks the layers of modern stress — from trauma and environment to community and purpose — and offers practical, embodied tools to restore calm, clarity, and resilience.     What You'll Learn 00:00:00 – Welcome to Super Life: Solutions for a Healthier Life and Better World 00:00:32 – Sponsor Spotlight: TheraSauna - Natural Healing Technologies (15% off with code Darrandai) 00:02:10 – The Super Life Podcast: Finding Contentment, Happiness, and Purpose 00:02:51 – Today's Topic: Stress - Reframing Stress as an Ally and Dashboard Light 00:04:54 – The "No Choice" Universe: Reconnecting to Infinite Possibilities 00:05:16 – The Reality of Stress: Statistics and the Impact of Chronic Stress 00:06:21 – Stress is Layered: Beyond a Single Cause, Addressing Chronic Stress 00:08:29 – Solutions for a Super Life: Safety over Calm and the Vagal Response 00:09:38 – The Inner Dialogue Layer: Trauma, Unconsciousness, and Spiritual Bypassing 00:11:47 – The Social Field Layer: Relationships, Community, and Finding Your Way Home 00:14:20 – Sponsor Spotlight: Bite Toothpaste - Sustainable, Non-Toxic Tabs (20% off with code Darin20) 00:16:35 – Creating Your Own Vision: Setting Boundaries with Media and Social Algorithms 00:17:29 – Finding Your Purpose: From Raising Children to Healing Injuries 00:18:35 – Environmental and Existential Stress Layers: Clutter, Noise, and Service 00:19:26 – Stress Load and Resiliency: Why Small Triggers Cause Blow-Ups 00:20:02 – Understanding the Dashboard Light: Acknowledging Unwillingness 00:20:35 – Safety as the Signal: Body Relaxation and Providing Inner Security 00:23:44 – Reframing Trauma: Was it the Protector You Needed at the Time? 00:25:00 – Releasing Trauma: Techniques, The Healing Code, and Waking the Tiger 00:26:06 – Finishing the Survival Response: Shaking, Crying, Screaming, and Stretching 00:26:38 – Stress as a Multiplier: Impact on Immune System, Heart, and Aging 00:28:10 – Stress Slows Repair: Inflammation, Cardiovascular Risk, and Cellular Aging 00:29:48 – The Integrative Approach: Changing Your Environments to Support Anti-Stress 00:30:07 – Actionable Stress Solutions: Circadian Rhythm, Nature, and Noise Reduction 00:30:44 – Actionable Stress Solutions: Gratitude, Conscious Breath, and Movement 00:31:32 – Energy Drains to Eliminate: Conflict, Clutter, Scrolling, and Late Caffeine 00:32:17 – Connecting to Greater Purpose: The Super Life Patreon Platform 00:32:54 – Morning/Night Questions: Letting Go, Creating, and Contributing 00:33:17 – Final Toolkit: Slow Breathing, Movement, Nature, Sauna, and Sleep 00:34:25 – The Invitation: Digging into all Layers of a Super Life on Patreon   Thank You to Our Sponsors Therasage: Go to www.therasage.com and use code DARIN at checkout for 15% off Bite Toothpaste: Go to trybite.com/DARIN20 or use code DARIN20 for 20% off your first order. Find More from Darin Olien: Instagram: @darinolien Podcast: SuperLife Podcast Website: superlife.com Book: Fatal Conveniences   Key Takeaway "Stress isn't your enemy — it's your compass. Every wave of tension points you back to what's asking for care, attention, and love. When you stop fighting stress and start listening to it, you don't just survive — you evolve."       Bibliography (selected, peer-reviewed) Sources: Gallup Global Emotions (2024); Gallup U.S. polling (2024); APA Stress in America (2023); Natarajan et al., Lancet Digital Health (2020); Orini et al., UK Biobank (2023); Martinez et al. (2022); Leiden University (2025). Cohen S, Tyrrell DA, Smith AP. Psychological stress and susceptibility to the common cold. N Engl J Med.1991;325(9):606–612. New England Journal of Medicine Cohen S, et al. Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc Natl Acad Sci USA. 2012;109(16):5995–5999. PNAS Kiecolt-Glaser JK, et al. Slowing of wound healing by psychological stress. Lancet. 1995;346(8984):1194–1196. The Lancet Kiecolt-Glaser JK, et al. Hostile marital interactions, proinflammatory cytokine production, and wound healing.Arch Gen Psychiatry. 2005;62(12):1377–1384. JAMA Network Tawakol A, et al. Relation between resting amygdalar activity and cardiovascular events. Lancet.2017;389(10071):834–845. The Lancet Epel ES, et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci USA.2004;101(49):17312–17315. PNAS McEwen BS, Stellar E. Stress and the individual: mechanisms leading to disease. Arch Intern Med.1993;153(18):2093–2101. PubMed McEwen BS, Wingfield JC. Allostasis and allostatic load. Ann N Y Acad Sci. 1998;840:33–44. PubMed Felitti VJ, et al. Relationship of childhood abuse and household dysfunction to many leading causes of death in adults (ACE Study). Am J Prev Med. 1998;14(4):245–258. AJP Mon Online Edmondson D, et al. PTSD and cardiovascular disease. Ann Behav Med. 2017;51(3):316–327. PMC Afari N, et al. Psychological trauma and functional somatic syndromes: a systematic review and meta-analysis.Psychosom Med. 2014;76(1):2–11. PMC Goyal M, et al. Meditation programs for psychological stress and well-being: a systematic review and meta-analysis. JAMA Intern Med. 2014;174(3):357–368. PMC Qiu Q, et al. Forest therapy: effects on blood pressure and salivary cortisol—a meta-analysis. Int J Environ Res Public Health. 2022;20(1):458. PMC Laukkanen T, et al. Sauna bathing and reduced fatal CVD and all-cause mortality. JAMA Intern Med.2015;175(4):542–548. JAMA Network Zureigat H, et al. Physical activity lowers CVD risk by reducing stress-related neural activity. J Am Coll Cardiol.2024;83(16):1532–1546. PMC Holt-Lunstad J, Smith TB, Layton JB. Social relationships and mortality risk: a meta-analytic review. PLoS Med.2010;7(7):e1000316. PMC Chen Y-R, Hung K-W. EMDR for PTSD: meta-analysis of RCTs. PLoS One. 2014;9(8):e103676. PLOS Hoppen TH, et al. Network/pairwise meta-analysis of PTSD psychotherapies—TF-CBT highest efficacy overall.Psychol Med. 2023;53(14):6360–6374. PubMed van der Kolk BA, et al. Yoga as an adjunctive treatment for PTSD: RCT. J Clin Psychiatry. 2014;75(6):e559–e565. PubMed Kelly U, et al. Trauma-center trauma-sensitive yoga vs CPT in women veterans: RCT. JAMA Netw Open.2023;6(11):e2342214. JAMA Network Bentley TGK, et al. Breathing practices for stress and anxiety reduction: components that matter. Behav Sci (Basel). 2023;13(9):756. 

In this first instalment of a two-part exclusive, The Food Professor Podcast sits down in person with Michael Medline, (now) former President and CEO of Empire Company Limited and Sobeys, in what serendipitously became his last official interview before news broke of his transition to lead The Woodbridge Company. Michael offers a rare, deeply personal look at his eight-plus-year tenure transforming one of Canada's largest retailers. He recounts stepping into the role in 2017, reshaping strategy, modernizing systems, and fostering a culture built on values, innovation, and operational excellence.Michael reflects on navigating the massive disruptions of recent years—from COVID-19 to global trade volatility and technological upheaval—while maintaining a clear North Star for the organisation. He shares insights on revitalizing store formats, strengthening private-label programs, and embracing data transformation and automation to sharpen competitiveness. The conversation also explores the bold acquisitions of Farm Boy and Longo's, discussing trust, partnership, culture, and why collaborative integration—not assimilation—is essential to preserving what makes independent banners special.He also speaks candidly about leadership: prioritizing people, resisting micromanagement, nurturing talent, and ensuring a national grocer performs as one unified organisation rather than fragmented regional fiefdoms. Medline's reflections on turning around the Safeway acquisition, advancing omnichannel capabilities through Voilà, and pushing Empire's innovation agenda offer invaluable lessons for retail leaders navigating rapid change.The episode also features a wide-ranging news conversation with Sylvain and Michael. They break down meat-industry dynamics on both sides of the Canada–U.S. border, including beef supply challenges, oligopoly concerns, and the impact of interprovincial trade barriers on Canadian prices. The hosts also explore the “protein orphan” trend driving increased chicken consumption—and the resulting supply management shortfalls—plus the social-media-fuelled surge in cottage cheese demand.Additional segments highlight CFIA's quietly formed task force responding to U.S. regulatory instability, early snowfall's potential impact on holiday shopping, and the growing disconnect between global climate COP events and the real-world policy outcomes they aim to influence.  The Food Professor #podcast is presented by Caddle. About UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa. Michael LeBlanc is the president and founder of M.E. LeBlanc & Company Inc, a senior retail advisor, keynote speaker and now, media entrepreneur. He has been on the front lines of retail industry change for his entire career. Michael has delivered keynotes, hosted fire-side discussions and participated worldwide in thought leadership panels, most recently on the main stage in Toronto at Retail Council of Canada's Retail Marketing conference with leaders from Walmart & Google. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, CanWest Media, Pandora Jewellery, The Shopping Channel and Retail Council of Canada to his advisory, speaking and media practice.Michael produces and hosts a network of leading retail trade podcasts, including the award-winning No.1 independent retail industry podcast in America, Remarkable Retail with his partner, Dallas-based best-selling author Steve Dennis; Canada's top retail industry podcast The Voice of Retail and Canada's top food industry and one of the top Canadian-produced management independent podcasts in the country, The Food Professor with Dr. Sylvain Charlebois from Dalhousie University in Halifax.Rethink Retail has recognized Michael as one of the top global retail experts for the fourth year in a row, Thinkers 360 has named him on of the Top 50 global thought leaders in retail, RTIH has named him a top 100 global though leader in retail technology and Coresight Research has named Michael a Retail AI Influencer. If you are a BBQ fan, you can tune into Michael's cooking show, Last Request BBQ, on YouTube, Instagram, X and yes, TikTok.Michael is available for keynote presentations helping retailers, brands and retail industry insiders explaining the current state and future of the retail industry in North America and around the world.

In this episode, I explore the critical role of cellular hydration as the foundational first step in the seven naturopathic steps to treatment to optimise health. Join me as I talk about why proper hydration goes far beyond just drinking water, how chronic dehydration impacts inflammation, hormone balance, and fertility at the cellular level, and the three progressive stages to restoring optimal hydration in your body. I'll unpack the science behind cellular hydration, explain why your cholesterol might actually be a dehydration response, and provide insights and actionable tips to help you build the foundation your body needs to reduce inflammation, support hormone balance, and optimise your fertility journey. A number of actionable tips were discussed including how to recognise signs of chronic dehydration, which foods and drinks are secretly dehydrating you, the proper omega-3 to omega-6 ratio for reducing inflammation, how to implement the three-stage hydration protocol, and why you should consider taking a break from supplements while you establish proper hydration. Episode Highlights: Why hydration is the foundation The 3-Stage Hydration Protocol The seed oil crisis and cell membranes Magnesium—your fertility secret weapon Why your supplements might not be working References: Häussinger D, Roth E, Lang F, Gerok W. Cellular hydration state: an important determinant of protein catabolism in health and disease. Lancet. 1993;341(8856):1330-1332. Bulun SE, Yilmaz BD, Sison C, et al. Endometriosis. Endocr Rev. 2019;40(4):1048-1079. Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10(5):261-275. Bulletti C, Coccia ME, Battistoni S, Borini A. Endometriosis and infertility. J Assist Reprod Genet. 2010;27(8):441-447. Damir HA, Ali MA, Adem MA, et al. The effect of long-term dehydration and subsequent rehydration on markers of inflammation, oxidative stress and apoptosis in the camel kidney. BMC Vet Res. 2020;16(1):437. Doktorova M, Heberle FA, Katsaras J, et al. Dehydration of lipid membranes drives redistribution of cholesterol between lateral domains. J Phys Chem Lett. 2024;15(17):4693-4700. Giudice LC. Clinical practice. Endometriosis. N Engl J Med. 2010;362(25):2389-2398. Marziali M, Venza M, Lazzaro S, Lazzaro A, Micossi C, Stolfi VM. Gluten-free diet: a new strategy for management of painful endometriosis related symptoms? Minerva Chir. 2012;67(6):499-504. Calder PC. Functional roles of fatty acids and their effects on human health. JPEN J Parenter Enteral Nutr. 2015;39(1 Suppl):18S-32S. Macer ML, Taylor HS. Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility. Obstet Gynecol Clin North Am. 2012;39(4):535-549. >>Endo Fertility Podcast Goodie Bag

The ARRIVE Trial and the Term Breech Trial reshaped modern birth practices in ways researchers never intended. From skyrocketing inductions to the loss of vaginal breech training, these studies reveal how even “gold-standard” science can miss the human side of birth.Clara invites you to take a mindful pause: to look beyond the data, question how evidence gets translated into policy, get curious about how the research was designed, and remember that true evidence-based care must center the individual—not just the research.You'll Learn:What the ARRIVE Trial and the Term Breech Trial actually found (and what they didn't)How these studies shifted policy, practice, and training worldwideWhy over-reliance on “evidence” can erase skills, intuition, and personal choiceHow to bring mindfulness into your decision-making about induction, breech birth, or any medical recommendationWhy traditional and holistic birth practices still matter—even if they've never been studiedMindful Reflection“Mindfulness isn't about ignoring evidence—it's about pausing long enough to ask, ‘Does this research apply to me, in my body, in this context?' True evidence-based care is a dialogue between research, clinician experience, and your own wisdom.”Resources MentionedDownload Clara's Free Birth Plan Template, used at over 5,000 births.Ready for an evidence based birth class? Check out A Path to A Powerful BirthThe Birth Advocacy Toolkit is a great option for expectant parents who have already taken a class but want to make sure their preferences are heard and want evidence based information to help make their decisions. Evidence Based Birth: Evidence on the ARRIVE Trial and Elective Induction at 39 WeeksEvidence Based Birth: Evidence on Breech BirthGrobman WA, et al. Labor Induction versus Expectant Management in Low-Risk Nulliparous Women. NEJM, 2018.Evidence Based Birth: “Evidence on the ARRIVE Trial and Elective Induction at 39 Weeks.”Nethery E, et al. Obstet Gynecol, 2023. Post-ARRIVE induction impact study.Hannah ME, et al. Planned Cesarean vs Planned Vaginal Birth for Breech. Lancet, 2000.Kotaska A. BMJ, 2004. “Inappropriateness of RCTs for complex intrapartum phenomena.”Goffinet F, et al. PREMODA Study. Am J Obstet Gynecol, 2006.RCOG Green-top Guideline No. 20b (2017).ACOG Committee Opinion No. 745 (2018).SOGC No. 384 (2019).Get 20% off your first monthly subscription with NEEDED Vitamins 

Send us a textA new report on health and climate change paints the grimmest picture yet about what's going on – not just that 2024 was the hottest year on record, but evidence that many governments have stopped even pretending to try to do anything about it.The 2025 Lancet Countdown on Health and Climate Change finds that more than half a million people die every year from heat-related causes, up 23 percent since the 1990s. Air pollution just from wildfire smoke was linked to 154,000 deaths in 2024. And 2.5 million people die every year because of the continued burning of fossil fuels, the report says.But Dr. Tafadzwa Mabhaudhi, Professor of Climate Change, Food Systems, and Health at the London School of Hygiene and Tropical Medicine, and Director of the Lancet Countdown in Africa, says it's not all bad news. Communities, people acting in groups, city governments, and others can make a difference.“We do have the power,” says Tafadzwa, who joins One World, One Health host Maggie Fox in this episode to talk about the report and what he sees for the future.African nations, especially, have the opportunity to show the way as they build cities that take advantage of clean energy, says Tafadzwa, who is also a professor in the Department of Plant and Soil Sciences, Future Africa, at the University of Pretoria in South Africa.The report finds hope in this trend, and estimates 160,000 lives are being saved annually as communities shift away from coal and enjoy cleaner air.Listen as Tafadzwa describes some of the successes in fighting climate change and what people and communities can do to encourage their governments to act.

C'est un scénario qui semble tout droit sorti d'un film, et pourtant il est bien réel : une simple visite chez le coiffeur peut, dans de très rares cas, provoquer un accident vasculaire cérébral. Ce phénomène porte un nom : le “syndrome du coiffeur”, ou plus précisément, le “syndrome du salon de beauté” (beauty parlor stroke syndrome).Le danger ne vient pas du shampoing lui-même, ni des produits utilisés, mais de la position du cou pendant le lavage. Lorsqu'on s'installe dans le bac à shampoing, la tête est souvent rejetée en arrière, parfois à un angle trop prononcé. Cette posture peut comprimer ou étirer les artères vertébrales, deux vaisseaux situés à la base du cou qui alimentent le cerveau en sang.Chez certaines personnes – en particulier celles ayant une fragilité de la paroi artérielle, une hypertension ou de l'arthrose cervicale –, ce mouvement peut provoquer une dissection de l'artère vertébrale. En clair : la paroi interne du vaisseau se déchire, le sang s'y infiltre, forme un caillot, et ce caillot peut ensuite migrer jusqu'au cerveau, entraînant un AVC.Les premiers cas ont été décrits dans les années 1990 dans des revues médicales comme The Lancet ou Stroke. Depuis, d'autres rapports ont confirmé l'existence de ce risque, bien que très faible. On parle d'un phénomène exceptionnel, mais suffisamment sérieux pour être connu des professionnels de santé. Les symptômes apparaissent parfois plusieurs heures après le passage chez le coiffeur : vertiges, troubles de la vision, nausées, faiblesse d'un côté du corps… Des signes à ne jamais ignorer.Certains facteurs augmentent la vulnérabilité : les troubles vasculaires, le tabagisme, les contraceptifs hormonaux, ou simplement une raideur du cou. C'est pourquoi les médecins recommandent d'éviter les extensions extrêmes de la nuque et de demander un appui dorsal adapté lors du shampoing.Aujourd'hui, beaucoup de salons ont ajusté leurs équipements, notamment avec des bacs inclinables et des coussins ergonomiques. Mais le message reste clair : un geste anodin peut devenir dangereux si la tête est trop basculée en arrière trop longtemps.Le “syndrome du coiffeur” nous rappelle que le corps humain est un système d'équilibres fragiles. Et qu'un simple moment de détente, mal positionné, peut avoir des conséquences graves — heureusement, rarissimes. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Overview: In this episode, Dr Gina Brown and Dr Sahar Khalili draw on their expertise in HIV prevention to provide an overview of the current PrEP landscape in the United States. They highlight advancements in HIV prevention and emphasize the importance of targeted programs to address disparities in access and uptake across population groups and geographic regions. The views expressed are those of the panelist(s) and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2025 and the content reflects the information available at that time. Guest: Gina Brown, MD; Sahar Khalili, PharmD   For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus  References ACOG. Preexposure prophylaxis for the prevention of human immunodeficiency virus. 2024. Available from: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2022/06/preexposure-prophylaxis-for-the-prevention-of-human-immunodeficiency-virus (Accessed June 25, 2025). ADAP Directory. About. 2024. Available from: https://adap.directory/about (Accessed June 25, 2025). Aidsmap. Condoms. 2023. Available from: https://www.aidsmap.com/about-hiv/condoms#toc-how-effective-are-condoms (Accessed June 25, 2025). AIDSVu. AIDSVu releases new PrEP data and launches PrEPVu.org, a new PrEP equity platform. 2024. Available from: https://aidsvu.org/news-updates/aidsvu-releases-new-prep-data-and-launches-prepvu-org-a-new-prep-equity-platform/ (Accessed June 25, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. AIDSVu. AIDSVu releases 2024 PrEP use data showing growing use across the U.S. 2025. Available from: https://aidsvu.org/news-updates/aidsvu-releases-2024-prep-use-data-showing-growing-use-across-the-u-s/ (Accessed July 18, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. AIDSVu. Location profiles: South. 2025. Available from: https://map.aidsvu.org/profiles/region/south/prevention-and-testing#1-2-PnR (Accessed July 31, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. AIDSVu. PrEP use significantly associated with decreasing new HIV diagnoses across U.S. states. 2025. Available from: https://aidsvu.org/news-updates/prep-use-significantly-associated-with-decreasing-new-hiv-diagnoses-across-u-s-states/ (Accessed June 25, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. Baeten J et al. Curr HIV/AIDS Rep 2013;10:142–51. Bekker LG et al. N Engl J Med 2024;391:1179–92. CDC. About ending the HIV epidemic in the US. 2024. Available from: https://www.cdc.gov/ehe/php/about/index.html (Accessed June 2, 2025). CDC. Clinical Guidance for PrEP. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/prep/index.html (Accessed June 25, 2025). CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2021 update. 2021. Available from: https://stacks.cdc.gov/view/cdc/112360 (Accessed June 25, 2025). Coates TJ et al. Lancet 2008;372:669–84. DHHS. Pre-exposure (PrEP) to prevent HIV during periconception, antepartum, ad postpartum. 2024. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/perinatal-hiv/pre-exposure-prophylaxis-prep-prevent-hiv-perinatal.pdf (Accessed June 25, 2025). Gandhi RT et al. JAMA 2023;329:63–84. HIV.gov. HIV treatment as prevention. 2023. Available from: https://www.hiv.gov/tasp (Accessed June 25, 2025). HIV.gov. Key EHE strategies. 2024. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/key-strategies (Accessed June 2, 2025). HIV.gov. Pre-exposure prophylaxis. 2025. Available from: https://www.hiv.gov/hiv-basics/hiv-prevention/using-hiv-medication-to-reduce-risk/pre-exposure-prophylaxis (Accessed June 25, 2025). Kelley CF et al. N Engl J Med 2025;392:1261–76. Kourtis AP et al. Ann Epidemiol 2025:106:48-54. Landers S et al. Am J Public Health 2017;107:1534–35. Landovitz RJ et al. N Engl J Med 2021;385:595–608. NIH. HIV and sexually transmitted infections (STIs). 2021. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-sexually-transmitted-diseases-stds (Accessed June 25, 2025). NIH. HIV medicines during pregnancy and childbirth. 2025. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-medicines-during-pregnancy-and-childbirth (Accessed July 31, 2025) NIH. Post-exposure prophylaxis (PEP). 2025. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/post-exposure-prophylaxis-pep (Accessed June 25, 2025). NIH. PrEP to prevent HIV and promote sexual health. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556471/ (Accessed June 25 2025). Siegler AJ et al. Ann Epidemiol 2020;45:24–31.e37 Sullivan PS et al. J Int AIDS Soc 2025;28:e26459. Townes A et al. Obstet Gynecol 2023;143:294–301. Underhill K et al. PLoS Med 2007;4:e275. United States Census Bureau. National population by characteristics: 2020–2024. 2024. Available from: https://www.census.gov/data/tables/time-series/demo/popest/2020s-national-detail.html (Accessed June 25, 2025). Owens DK et al. JAMA 2019;321:2326–36. Vermund SH et al. J Acquir Immune Defic Syndr 2013;63:S12–25. Washington State Department of Health. Pre-exposure prophylaxis drug assistance program (PrEP DAP). Available from: https://doh.wa.gov/you-and-your-family/illness-and-disease-z/hiv/prevention/pre-exposure-prophylaxis-drug-assistance-program-prep-dap (Accessed June 25, 2025). World Health Organization. Global HIV programme: pre-exposure prophylaxis (PrEP). Available from: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/prevention/pre-exposure-prophylaxis (Accessed June 25, 2025).

Overview: In this episode, Dr Joel Gallant gives a history of antiretroviral therapy and HIV drug resistance, drawing on his personal and professional experience beginning in the early 1980s. The views expressed are those of the panelist and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2023 and the content reflects the information available at that time. Guest: Joel Gallant, MD, MPH    For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus    References AIDSVu.org. New HIV diagnoses. 2023. Available from: https://aidsvu.org/local-data/united-states/south/ (Accessed May 19, 2025) AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. Alonso A, de Irala J. Strategies in HIV prevention: the A-B-C approach. Lancet 2004;364:1033. Available from: https://doi.org/10.1016/s0140-6736(04)17050-5 Bacheler L, Jeffrey S, Hanna G et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001;75:4999–5008. Available from: https://doi.org/10.1128/jvi.75.11.4999-5008.2001 Barré-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868–71. Available from: https://doi.org/10.1126/science.6189183 Bayer R, Edington C. HIV testing, human rights, and global AIDS policy: exceptionalism and its discontents. J Health Polit Policy Law 2009;34:301–23. Available from: https://doi.org/10.1215/03616878-2009-002 Centers for Disease Control and Prevention. Pneumocystis pneumonia – Los Angeles. MMWR Morb Mortal Wkly Rep 1981;30:250-2. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/june_5.htm Centers for Disease Control and Prevention. Preventing HIV. 2024. Available from: https://www.cdc.gov/hiv/prevention/index.html (Accessed May 22, 2025) Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493–505. Available from: https://doi.org/10.1056/NEJMoa1105243 Cuevas JM, Geller R, Garijo R et al. Extremely high mutation rate of HIV-1 in vivo. PLoS Biol 2015;13:e1002251. Available from: https://doi.org/10.1371/journal.pbio.1002251 Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/optimizing-antiretroviral-therapy (Accessed May 19, 2025) Dragovic G. Acute pancreatitis in HIV/AIDS patients: an issue of concern. Asian Pac J Trop Biomed 2013;3:422–425. Available from: https://doi.org/10.1016%2FS2221-1691(13)60091-X Eron JJ, Benoit SL, Jemsek J et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995;333:1662–9. Available from: https://doi.org/10.1056/nejm199512213332502 Gandhi RT, Tashima KT, Smeaton LM et al. Long-term outcomes in a large randomized trial of HIV-1 salvage therapy: 96-week results of AIDS clinical trials group A5241 (OPTIONS). J Infect Dis 2020;221:1407–15. Available from: https://doi.org/10.1093/infdis/jiz281 Getting to Zero San Francisco. HIV epidemiology annual report 2017. 2022. Available from: https://gettingtozerosf.org/getting-to-zero-resources/hiv-report-2017/ (Accessed May 22, 2025) Global Fund. About the Global Fund. 2024. Available from: https://www.theglobalfund.org/en/about-the-global-fund/ (Accessed May 19, 2025) Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429–41. Available from: https://doi.org/10.1056/NEJMoa0803152 Gulick RM, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734–9. Available from: https://doi.org/10.1056/nejm199709113371102 Haubrich R, Berger D, Chiliade P et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007;21:F11–8. Available from: https://doi.org/10.1097/QAD.0b013e3280b07b47 HIV Prevention Trials Network. HPTN 052. 2023. Available from: https://www.hptn.org/research/studies/hptn052 (Accessed May 19, 2025) HIV.gov. HIV and AIDS timeline. 2024. Available from: https://www.hiv.gov/hiv-basics/overview/history/hiv-and-aids-timeline/ (Accessed May 19, 2025) HIVinfo.NIH.gov. FDA approval of HIV medicines. 2024. Available from: https://hivinfo.nih.gov/understanding-hiv/infographics/fda-approval-hiv-medicines (Accessed May 19, 2025) i-base. Cross-resistance by drug class. 2025. Available from: https://i-base.info/guides/changing/cross-resistance (Accessed May 19, 2025) Iyidogan P, Anderson KS. Current perspectives on HIV-1 antiretroviral drug resistance. Viruses 2014;6:4095–139. Available from: https://doi.org/10.3390/v6104095 Lalezari JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175–85. Available from: https://doi.org/10.1056/NEJMoa035026 Landovitz RJ, Donnell D, Clement ME et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med 2021;385:595–608. Available from: https://doi.org/10.1056/NEJMoa2101016 Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731–4. Available from: https://doi.org/10.1126/science.2467383 Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007;44:179–87. Available from: https://doi.org/10.1097/01.qai.0000247229.68246.c5 Lucas C. The San Francisco model and the nurses of Ward 5B. Lancet HIV 2019;6:E819. Available from: https://doi.org/10.1016/S2352-3018(19)30267-X Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29–38. Available from: https://doi.org/10.1016/s0140-6736(07)61047-2 Marcelin AG. Resistance to nucleoside reverse transcriptase inhibitors. In: Geretti AM, editor. Antiretroviral Resistance in Clinical Practice. London: Mediscript; 2006. Chapter 1. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2241/ Margolis AM, Heverling H, Pham PA et al. A review of the toxicity of HIV medications. J Med Toxicol 2014;10:26–39. Available from: https://doi.org/10.1007/s13181-013-0325-8 Moore RD, Creagh-Kirk T, Keruly J et al. Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Zidovudine Epidemiology Study Group. Arch Intern Med 1991;151:981–6. Available from: https://doi.org/10.1001/archinte.1991.00400050123023 National Institute of Allergy and Infectious Diseases. HIV Undetectable = Untransmittable (U = U), or treatment as prevention. 2019. Available from: https://www.niaid.nih.gov/diseases-conditions/treatment-prevention (Accessed May 19, 2025) Nelson MR, Katlama C, Montaner JS et al. The safety of […] for the treatment of HIV infection in adults: the first 4 years. AIDS 2007;21:1273–81. Available from: https://doi.org/10.1097/QAD.0b013e3280b07b33 New York State Department of Health. Pre-exposure prophylaxis (PrEP) to prevent HIV infection: question and answers. 2012. Available from: https://www.health.ny.gov/publications/0265/ (Accessed May 22, 2025) Overton ET, Richmond G, Rizzardini G et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin Infect Dis 2023;76:1646–54. Available from: https://doi.org/10.1093/cid/ciad020 Pollak EB, Parmar M. Indinavir. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554396/ (Accessed May 19, 2025) Richman DD, Fischl MA, Grieco MH et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:192–7. Available from: https://doi.org/10.1056/nejm198707233170402 Schmit JC, Ruiz L, Clotet B et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996;10:995–9. Available from: https://doi.org/10.1097/00002030-199610090-00010 Siliciano JD, Kajdas J, Finzi D et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003;9:727–8. Available from: https://doi.org/10.1038/nm880 Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339–54. Available from: https://doi.org/10.1056/NEJMoa0708975 TIME. Man of the year. 1996. Available from: https://time.com/vault/issue/1996-12-30/page/1/ (Accessed May 19, 2025) U.S. President's Emergency Plan for AIDS Relief (PEPFAR). About us. 2025. Available from: https://www.state.gov/about-us-pepfar/ (Accessed May 19, 2025)

About this Episode Episode 50 of “The 2 View” – BNPs, D-Dimers, and Sneakily Sick Kids Segment 1A - Needs of older nurses Clendon JA, Walker L. Nurses aged over 50 and their perceptions of flexible working: The experiences and needs of older nurses in relation to flexible working and the barriers and facilitators to implementation within workplaces. J Nurs Manag. 2016;24:336-346. doi:10.1111/jonm.12325 Segment 1B - WHO and Tropical Diseases Special Programme for Research and Training in Tropical Diseases. World Health Organization. Accessed August 19, 2025. https://tdr.who.int/about-us Segment 2A - BNP Silvers SM, Gemme SR, Hickey S, et al. Clinical Policy: Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department With Acute Heart Failure Syndromes. Ann Emerg Med. 2019;49(2): 232–241. Lamberta M, Chertoff A. BNP Level in the Emergency Department: Does it Change Management? EMDocs. June 20, 2016. Accessed November 4, 2025. https://www.emdocs.net/bnp-level-in-the-emergency-department-does-it-change-management/ Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167. doi: 10.1056/NEJMoa020233 Segment 2B - D-Dimer Wolf SJ, Hahn SA, Nentwich LM, et al. Clinical policy: Critical issues in the evaluation and management of adult patients presenting to the emergency department with suspected acute venous thromboembolic disease. Ann Emerg Med. 2018;71(5):e59–e109. doi:10.1016/j.annemergmed.2018.03.006 Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: The ADJUST-PE study. JAMA. 2014;311(11):1117–1124. doi:10.1001/jama.2014.2135 van der Hulle T, Cheung WY, Kooij S, et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): A prospective, multicentre, cohort study. Lancet. 2017;390(10091):289–297. doi:10.1016/S0140-6736(17)30885-1 Kearon C, de Wit K, Parpia S, et al. Diagnosis of pulmonary embolism with D-dimer adjusted to clinical probability. N Engl J Med. 2019;381(22):2125–2134. doi:10.1056/NEJMoa1909159 Lim w, Le Gal G, Bates SM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: Diagnosis of venous thromboembolism. Blood Adv. 2018;2(22):3226-3256. doi:10.1182/bloodadvances.2018024828 Kabrhel C, Jaff MR, Channick RN. D-dimer. StatPearls. June 22, 2025. Accessed November 4, 2025. https://www.ncbi.nlm.nih.gov/books/NBK431064/ Tripodi A, Lippi G. How we manage a high D-dimer. Haematologica. 2020;106(6):1491-1494. doi:10.3324/haematol.2020.248344 Segment 3: Sneakily Sick Kids Kocher MS, Zurakowski D, Kasser JR. Differentiating between septic arthritis and transient synovitis of the hip in children: An evidence-based clinical prediction algorithm. J Bone Joint Surg Am. 1999;81(12):1662-1670. doi:10.2106/00004623-199912000-00002 Caird MS, Flynn JM, Leung YL, et al. Factors distinguishing septic arthritis from transient synovitis of the hip in children: a prospective study. J Bone Joint Surg Am. 2006;88(6): 1251-1257. doi:10.2106/JBJS.E.00216 Recurring Sources Center for Medical Education. http://ccme.org The Proceduralist. http://www.theproceduralist.org The Procedural Pause. https://journals.lww.com/em-news/blog/theproceduralpause/pages/default.aspx The Skeptics Guide to Emergency Medicine. http://www.thesgem.com Be sure to keep tuning in for more great prizes and fun trivia questions! Once you hear the question, please email us your guesses at 2viewcast@gmail.com and tell us who you want to give a shout-out to.

Send us a message with this link, we would love to hear from you. Standard message rates may apply.We break down osteopenia and osteoporosis with clear steps to protect independence: how bones weaken, how DEXA scoring works, and which daily habits reduce fracture risk. We share nutrition, exercise, lifestyle changes, and home safety that make a measurable difference.• key stats on fracture risk in women and men over 50• definitions of osteopenia and osteoporosis using T-scores• hip, spine and wrist as common fracture sites• why bone loss accelerates after menopause• risk factors including family history, smoking and low weight• DEXA scan basics and when to ask for screening• calcium and vitamin D targets and food sources• Mediterranean diet, protein and supportive micronutrients• weight-bearing, resistance and balance training essentials• Tai Chi and fall risk reduction• home safety changes that prevent falls• when medications like bisphosphonates or denosumab help• practical questions to ask your clinicianReferences1. Osteoporosis: Common Questions and Answers. Harris K, Zagar CA, Lawrence KV. American Family Physician. 2023;107(3):238-246.2. Postmenopausal Osteoporosis. Walker MD, Shane E. The New England Journal of Medicine. 2023;389(21):1979-1991. doi:10.1056/NEJMcp2307353.3. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update. Camacho PM, Petak SM, Binkley N, et al. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2020;26(Suppl 1):1-46. doi:10.4158/GL-2020-0524SUPPL.4. Global, Regional Prevalence, and Risk Factors of Osteoporosis According to the World Health Organization Diagnostic Criteria: A Systematic Review and Meta-Analysis. Xiao PL, Cui AY, Hsu CJ, et al. Osteoporosis International : A Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2022;33(10):2137-2153. doi:10.1007/s00198-022-06454-3.5. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. Curry SJ, Krist AH, Owens DK, et al. JAMA. 2018;319(24):2521-2531. doi:10.1001/jama.2018.7498.6. The Cost of Osteoporosis, Osteopenia, and Associated Fractures in Australia in 2017. Tatangelo G, Watts J, Lim K, et al. Journal of Bone and Mineral Research : The Official Journal of the American Society for Bone and Mineral Research. 2019;34(4):616-625. doi:10.1002/jbmr.3640.7. The Prevalence and Treatment Rate Trends of Osteoporosis in Postmenopausal Women. Zhang X, Wang Z, Zhang D, et al. PloS One. 2023;18(9):e0290289. doi:10.1371/journal.pone.0290289.8. Osteopenia: A Key Target for Fracture Prevention. Reid IR, McClung MR. The Lancet. Diabetes & Endocrinology. 2024;12(11):856-864. doi:10.1016/S2213-8587(24)00225-0.9. Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-Analysis for the American College of Physicians. Ayers C, Kansagara D, Lazur B, et al. Annals of Internal Medicine. 2023;176(2):182-195. doi:10.7326/M22-0684.Support the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

Recorded live at the Coffee Association of Canada Annual Conference, this special edition of The Food Professor Podcast with Michael LeBlanc and Dr. Sylvain Charlebois brews up a rich conversation on the state of Canada's food economy, the coffee industry's shifting landscape, and the global forces shaping what Canadians eat and drink live on the stage.The episode opens with Michael and Sylvain diving into the latest geopolitical tensions influencing trade and agriculture. From Washington to Mexico City, Sylvain shares insights from his travels and firsthand discussions with U.S. policy insiders and Latin American producers. The conversation highlights how Canada's trading partners are adapting quickly, especially Mexico's resilience and growing potential as a key agri-food ally in the hemisphere.The professors then turn to an annual highlight — an early look at the 2026 Canada Food Price Report, compiled by a network of ten universities using AI-powered forecasting. Sylvain hints at tough times ahead for consumers, forecasting that meat and poultry prices could rise by as much as 25% in the months ahead, putting pressure on Canadian households. He connects this to the emerging “protein play” trend, where consumers are seeking protein in unconventional forms — including fortified beverages like coffee. While acknowledging the opportunity, he cautions that nutritionists are warning against over-fortification, signaling that balance and consumer education will be key.The discussion then flows into GLP-1 drugs and their growing impact on food demand. As consumers change their eating patterns, Sylvain warns that Big Pharma's gains may translate into Big Food's challenges — though innovation and reformulation could open new opportunities. From AI-enabled efficiency to personalized nutrition, the professors explore how food and beverage brands must adapt to new consumption realities.Rounding out the first half, they discuss the “Battle for the Third Place” — how coffee shops are redefining the space between home and work post-COVID. Sylvain urges operators to double down on human connection and service excellence, even as automation and rising wages push toward efficiency.In the second half, guest Doug Porter, Chief Economist at BMO, unpacks Canada's economic outlook. Porter delivers a grounded view of growth, inflation, immigration, and consumer spending, labeling the new federal budget “boring — and that's a good thing.” He weighs in on labour shortages, immigration reform, the “K-shaped” economy, and AI's role in reshaping productivity, closing with optimism that innovation and adaptation — not fear — will guide Canada's next decade. The Food Professor #podcast is presented by Caddle. About UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa. Michael LeBlanc is the president and founder of M.E. LeBlanc & Company Inc, a senior retail advisor, keynote speaker and now, media entrepreneur. He has been on the front lines of retail industry change for his entire career. Michael has delivered keynotes, hosted fire-side discussions and participated worldwide in thought leadership panels, most recently on the main stage in Toronto at Retail Council of Canada's Retail Marketing conference with leaders from Walmart & Google. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, CanWest Media, Pandora Jewellery, The Shopping Channel and Retail Council of Canada to his advisory, speaking and media practice.Michael produces and hosts a network of leading retail trade podcasts, including the award-winning No.1 independent retail industry podcast in America, Remarkable Retail with his partner, Dallas-based best-selling author Steve Dennis; Canada's top retail industry podcast The Voice of Retail and Canada's top food industry and one of the top Canadian-produced management independent podcasts in the country, The Food Professor with Dr. Sylvain Charlebois from Dalhousie University in Halifax.Rethink Retail has recognized Michael as one of the top global retail experts for the fourth year in a row, Thinkers 360 has named him on of the Top 50 global thought leaders in retail, RTIH has named him a top 100 global though leader in retail technology and Coresight Research has named Michael a Retail AI Influencer. If you are a BBQ fan, you can tune into Michael's cooking show, Last Request BBQ, on YouTube, Instagram, X and yes, TikTok.Michael is available for keynote presentations helping retailers, brands and retail industry insiders explaining the current state and future of the retail industry in North America and around the world.

Welcome to Ozempic Weightloss Unlocked, the show breaking down the latest news, research, and real-life stories around Ozempic, the medication making headlines for weight management and beyond.Today, we will dive into some of the biggest updates, from its impact on both weight loss and heart health, to new science on how the medication truly works—plus what listeners should know when considering this medication in their own lives.A recent comprehensive study led by University College London has revealed that Ozempic, which contains the active ingredient semaglutide, not only aids in weight reduction but also offers significant protection against heart attacks and other major heart events. The study, published in The Lancet, was conducted on over seventeen thousand adults who were overweight and had cardiovascular disease. Participants received weekly semaglutide injections or a placebo. Earlier findings showed a 20 percent reduction in the risk of heart attacks, strokes, and other major cardiac events among those on semaglutide.What makes these findings truly remarkable is that semaglutide's heart protection was seen in people across all body types. Adults whose body mass index was only slightly elevated, around twenty-seven, experienced the same level of cardiovascular protection as those with obesity. This means you do not have to be significantly overweight to benefit from the drug's heart-protective effects. According to the lead researcher Professor John Deanfield, this could reshape how and to whom Ozempic is prescribed in the future. He stated that limiting the use of the medication only to people with the highest body weights may not be the best policy, particularly for those who are looking to address cardiovascular risks.The study also highlighted that while a reduction in waist size does contribute to some of the heart protection—about one-third to be exact—the majority of heart health benefits cannot be explained by weight loss alone. Professor Deanfield emphasized that Ozempic directly impacts heart disease and other conditions associated with aging.These discoveries raise new questions about the potential long-term uses of Ozempic, not just as a tool for weight loss, but as a preventive therapy for aging-related diseases, especially cardiovascular disease.Of course, benefits must always be balanced against possible side effects. It is important to remember that while Ozempic can be a powerful medicine, it is not for everyone—and it is not a quick fix. According to recent real-world surveys published in Patient Preference and Adherence, a substantial majority, around seventy-two percent, of people who started Ozempic did so solely for weight loss, while another twenty percent used it for both weight control and diabetes management. Most initiated therapy at lower doses, with gradual increases over time.However, like any medication, Ozempic does carry risks. Users have reported gastrointestinal side effects including nausea and diarrhea. Rare but serious risks exist, such as concerns around thyroid tumors found in animal studies and pancreatitis. Long-term safety data is still being gathered, and health care providers weigh these factors when advising patients.Public awareness of Ozempic has been driven by direct-to-consumer advertising. New studies in the Journal of the American Medical Association dissect this trend, noting that advertising can influence patient expectations and prompt conversations with health care providers, but it also underscores the importance of educated decision making.With all these updates and the growing body of research, the most important advice is to consult a qualified health care provider before starting or stopping Ozempic or any weight loss medication. Each person's medical background and goals are unique. These new discoveries mean that more people than ever are wondering if Ozempic might be right for them—not just for weight management, but also as a tool to reduce long-term health risks.Thanks for joining us today on Ozempic Weightloss Unlocked. Remember to subscribe so you never miss the latest updates and expert insights. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Pelle Neroth Taylor is a Swedish-British journalist, filmmaker, and political writer based in Sweden, renowned for his investigative work on geopolitics, propaganda, political assassinations, and the rise of European populism. Educated at Westminster School and Bristol University, he began his career in the early 1990s reporting for The Economist from the post-communist Baltic States, later editing and contributing to outlets like The Guardian, The Independent on Sunday, The Times, Financial Times, Sunday Times, New Scientist, and The Lancet. As founder of Two Raven Films, he has produced documentaries such as Sweden, Dying to Be Multicultural, a critical examination of Sweden's immigration policies that has garnered over 2 million views on platforms like Amazon Prime and Blckbx TV, and Cancel Nation, addressing censorship and cancel culture. Tickets to Cornerstone Forum 26': https://www.showpass.com/cornerstone26/Tickets to the Mashspiel:https://www.showpass.com/mashspiel/Silver Gold Bull Links:Website: https://silvergoldbull.ca/Email: SNP@silvergoldbull.comText Grahame: (587) 441-9100Bow Valley Credit UnionBitcoin: www.bowvalleycu.com/en/personal/investing-wealth/bitcoin-gatewayEmail: welcome@BowValleycu.com Use the code “SNP” on all ordersProphet River Links:Website: store.prophetriver.com/Email: SNP@prophetriver.comGet your voice heard: Text Shaun 587-217-8500

A new era for complex mitral regurgitation. The ENCIRCLE pivotal trial in The Lancet reports that fully percutaneous, transfemoral, transseptal TMVR (SAPIEN M3) achieved durable MR reduction (≈96% ≤1+ at 1 year), low early mortality, and meaningful improvement in symptoms and quality of life for patients unsuitable for surgery or TEER.   A third pathway for mitral disease is emerging—one built on precision access, valve-in-valve durability planning, and advancing patient selection.   Innovation meeting clinical need.

The FiltrateJoel Topf‍ ‍@kidneyboy.bsky.social‬Swapnil Hiremath@hswapnil.medsky.socialAC @medpeedskidneys.bsky.socialSpecial GuestMike Walsh Associate Professor in the Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster University as well as a Scientist at the Population Health Research Institute and a nephrologist at St. Joseph's Healthcare Hamilton where he is the Chair of the Clinical Nephrology Research Group. Editing and Show Notes bySophia AmbrusoThe Kidney Connection written and performed by Tim YauShow NotesALCHEMIST (NephJC Shorts, Rossignol et al Lancet 2025)AC is in her 83rd year of med-peds fellowship.Joel's monologue brings us all down.Prophylactic ICD therapy doesn't improve sudden cardiac death or all-cause mortality in HD patients in the ICD2 trial (Jukema JW et al. Circulation 2019)Initiation with statins do not impact MACE endpoints or atherosclerotic events (4D AURORA trial Fellstrom BC et al. NEJM 2009 & SHARP trial Baigent C et al. Lancet 2011)Mike tries to liven up the mood by mentioning positive outcomes with iron therapy in heart failure with the PIVOTAL trial (Macdougall IC et al. NEJM 2018)TOPHAT trial revealed treatment with spironolactone in HFpEF did not affect MACE outcomes. (Pitt B et al. NEJM 2014)NephTrials ‘Run-in periods in clinical trials: What can we ACHIEVE?'SPIN D trial - spironolactone dose finding trial in ESRD (Charytan DM et al. Kidney Int 2018)Mike shares the human experience of the trial after being instructed to end the trial prematurely and being told they have “answered their question”Study in Japan - spironolactone predominantly benefits male over females (cannot find this)Male vs female benefit not observed in ACHIEVE despite Mike's initial hypothesisSwap compares and contrasts ACHIEVE, ALCHEMIST & Meta-analysis (Pyne L et al. Lancet 2025)Mike discusses how nonadherence to spironolactone impacted the intention to treat outcomes in the trial.What is a high risk of bias for dummies?Mike, Swap & Joel ponder future nsMRA or ASI trials hemodialysis?Tubular secretionsSwap is probably stalking Martha Wells by now, has moved on from Witch King, now onto Queen Demon on Good ReadsAC is adding to her brood, 2 dogs (Snickers & Harper), 1 childDungeon Crawler Call - a science fantasy book series by Matt Dinniman (on goodreads), which he lovingly referred to as complete nerd trash.Joel is binging on the series Task on HBO max, featuring Mark Ruffalo as FBI agent.NephJC is having its annual fundraiser (get your tickets here) at ASN. Providing a party shuttle that is leaving every 30 minutes from the conference center. As always, it will feature a live podcast recording covering the ASN late breaking, high impact clinical trials.Swap describes the high impact model at ASN this year - go big or go home.

Dr Gary Rodin discusses The human crisis in cancer: a Lancet Oncology Commission which identifies a growing imbalance between technological innovation and the human dimensions of cancer care.Click here to read the full Commission: The human crisis in cancer: a Lancet Oncology CommissionAnd comment: Re-establishing human-centred careTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Recent research has revealed that the heart health benefits of the weight loss drug Ozempic, which contains the active ingredient semaglutide, are not solely due to weight loss. A large study published in The Lancet and led by researchers at University College London analyzed data from more than seventeen thousand adults aged forty five and older who were overweight and had cardiovascular disease. The participants were randomly assigned to receive weekly injections of semaglutide or a placebo. The study found that semaglutide significantly reduced the risk of major cardiac events such as heart attacks, strokes, and cardiovascular deaths, regardless of how much weight each participant lost during the first four and a half months of treatment. This means that even people who lost little or no weight experienced similar heart protection as those who lost a substantial amount.The study also looked at the impact of waist circumference, which is a marker for visceral fat, and found that a reduction in waist size was linked to about one third of the heart benefits seen in patients taking semaglutide. However, the majority of the cardiovascular benefit was not explained by changes in weight or waist size alone. This suggests that semaglutide may have direct effects on the underlying causes of heart disease, beyond just helping people lose weight. Experts say this could mean the drug might be beneficial for patients who are not severely overweight, including those with BMIs in the normal range, although further research is needed to confirm this.Oprah Winfrey has recently spoken about her own experience with Ozempic, describing it as a tool she uses to manage her weight. She has emphasized that medication is not the only way to lose weight and that it should be seen as one option among many. Oprah has also discussed the broader cultural conversation around weight loss drugs, highlighting the need to address weight stigma and body shaming. Her openness has sparked a national dialogue about the role of prescription medications in weight management and the importance of focusing on overall health rather than just appearance.The findings from the latest research are prompting doctors and researchers to reconsider how they approach the treatment of obesity and heart disease. While Ozempic and similar drugs were originally developed for diabetes, their ability to protect the heart even without significant weight loss is a major development. This could lead to new treatment strategies for people at high risk of cardiovascular events, regardless of their body size. As the medical community continues to explore the full range of benefits and risks associated with these medications, the conversation around weight loss and heart health is becoming more nuanced and inclusive.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

In this flavorful new episode of The Food Professor Podcast—presented by Caddle—Michael LeBlanc and Dr. Sylvain Charlebois serve up an inspiring conversation with Rob Sengotta, chef and co-founder of Von Slick's Finishing Touch, the award-winning Manitoba-based producer of gourmet compound butters.The InterviewRob takes listeners behind the scenes of his chef-to-entrepreneur journey—from fine-dining kitchens in London and France to building a small-batch butter business on the prairies. He shares how curiosity and culinary discipline led to Von Slick's signature push-tube packaging and eight imaginative flavours, including garlic confit, roasted red pepper, mushroom duxelle, and cowboy butter.Listeners learn how Rob and partner Landon Craker turned a spark of an idea into a thriving Western Canadian brand by mastering distribution, leveraging farmers' markets, and staying creative on social media. Rob reflects on his early appearance on Dragon's Den, the lessons learned about timing and valuation, and the advantages of remaining proudly local. He also reveals new restaurant-format products, growing online sales nationwide, and why Canadians' appetite for supporting homegrown brands continues to expand.The NewsIn the first half, Sylvain reports live from Medellín, Colombia, where he's attending an international conference on rural food economies. He offers a fascinating window into Colombia's agricultural transformation—how coffee and cocoa remain vital exports and how farmers are striving to move beyond decades of narcotics-driven instability.Back in Canada, Michael and Sylvain unpack the latest headlines:CFIA factory inspections and the urgent need for transparency;Health Canada's cloned-meat consultations, why silent science can backfire, and the parallels to GMO controversies;Parliamentary hearings on the grocery code of conduct and why supplier–retailer trust still drives price volatility;Bank of Canada's rate decision, its implications for restaurants and food-service recovery; andThere is a growing debate over adopting a U.S.-style SNAP food-assistance program in Canada.This episode blends global perspective, policy insight, and entrepreneurial inspiration—proving again that from farm to fork, the Canadian food economy is as complex as it is delicious. The Food Professor #podcast is presented by Caddle. About UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa. Michael LeBlanc is the president and founder of M.E. LeBlanc & Company Inc, a senior retail advisor, keynote speaker and now, media entrepreneur. He has been on the front lines of retail industry change for his entire career. Michael has delivered keynotes, hosted fire-side discussions and participated worldwide in thought leadership panels, most recently on the main stage in Toronto at Retail Council of Canada's Retail Marketing conference with leaders from Walmart & Google. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, CanWest Media, Pandora Jewellery, The Shopping Channel and Retail Council of Canada to his advisory, speaking and media practice.Michael produces and hosts a network of leading retail trade podcasts, including the award-winning No.1 independent retail industry podcast in America, Remarkable Retail with his partner, Dallas-based best-selling author Steve Dennis; Canada's top retail industry podcast The Voice of Retail and Canada's top food industry and one of the top Canadian-produced management independent podcasts in the country, The Food Professor with Dr. Sylvain Charlebois from Dalhousie University in Halifax.Rethink Retail has recognized Michael as one of the top global retail experts for the fourth year in a row, Thinkers 360 has named him on of the Top 50 global thought leaders in retail, RTIH has named him a top 100 global though leader in retail technology and Coresight Research has named Michael a Retail AI Influencer. If you are a BBQ fan, you can tune into Michael's cooking show, Last Request BBQ, on YouTube, Instagram, X and yes, TikTok.Michael is available for keynote presentations helping retailers, brands and retail industry insiders explaining the current state and future of the retail industry in North America and around the world.

U.N. Secretary General Antonio Guterres has said that global warming will ‘inevitably' surpass 1.5 degrees. What does this mean for global health? The ninth annual Lancet report on health and climate could hold some answers.Also on the program, could contaminated meat be a source for some urinary tract infections? Professor Lance Price speaks about his new study finding a link between the two. Also on the program, could how we walk affect our health more than the distance we've travelled? Health journalist Layal Liverpool joins Claudia Hammond to discuss these stories and more. Presenter: Claudia Hammond with Layal Liverpool Producer: Hannah Robbins and Margaret Sessa-Hawkins with Alice McKee

複雜性創傷後壓力症（complex post-traumatic stress disorder，complex PTSD）在 ICD-11 中被列為「與壓力特別相關的疾病」，它和邊緣型人格障礙症（borderline personality disorder, BDP）是病因相同且相似的疾病，但你知道兩者的核心症狀有何異同嗎？想知道複雜性創傷後壓力症的評估重點以及治療原則又有哪些嗎？

D'après une récente étude publiée dans la revue médicale The Lancet, la France aurait le taux de cancer le plus élevé au monde après Monaco. Un classement inquiétant qui a fait couler beaucoup d'encre dans les médias français. Mais comment l'expliquer ? Est-ce à cause du mode de vie des Français, de facteurs environnementaux, ou simplement parce que leur système de santé détecte mieux les cancers ? Dans cet épisode, Hugo explore les raisons de ce phénomène. Il explique aussi pourquoi, malgré ces chiffres alarmants, les taux de survie restent parmi les meilleurs d'Europe. Enfin, il évoque les défis du système de santé français et l'importance cruciale du dépistage. Un sujet préoccupant... mais pas sans espoir ! Retrouvez la transcription de l'épisode sur www.innerfrench.com/e182 Retrouvez nos cours pour améliorez votre français sur www.courses.innerfrench.com

Dr. Dipen J. Parekh is a globally renowned urologic oncologist, healthcare innovator, and leader in academic medicine. He was appointed Executive Vice President for Health Affairs at the University of Miami and Chief Executive Officer of its health system (UHealth) on June 1, 2025. He remains Founding Director of the Desai Sethi Urology Institute and is an accomplished researcher and professor at the University of Miami Miller School of Medicine who holds the Victor A. Politano Endowed Chair in Urology and is widely celebrated for his groundbreaking contributions to the field of robotic-assisted urologic oncology. Having served as Chief Operating Officer of UHealth from 2020-2025, Chief Clinical Officer from 2017-2020, Chairman of the Department of Urology since 2012, Executive Dean of Clinical Affairs at the University of Miami Miller School of Medicine, and Director of Robotic Surgery for UHealth, Dr. Parekh brings a wealth of academic, clinical, administrative, and institutional experience to the role.Over the course of his career, Dr. Parekh has performed more than 6,000 robotic urologic cancer surgeries, making him one of the most experienced practitioners worldwide. He led the groundbreaking RAZOR trial, published in The Lancet in 2018, which established the efficacy of robotic-assisted radical cystectomy as comparable to open surgery for bladder cancer. He is an NCI funded surgeon scientist with over 200 peer reviewed publications in urologic oncology. His dedication to innovation has also included establishing advanced robotic surgery programs in academic centers across the globe.

In this special series on The Cardiovascular Outcome Trials our host, Dr. Neil Skolnik will discuss the history and importance of the Cardiovascular Outcome Trials for diabetes medications . In Part 1 we discuss an historical perspective with Dr. Steven Nissan and how this has lead to the CVOTs that change the way we practice from EMPA-REG in 2015 to SURPASS-CVOT in 2025. This special episode is supported by an independent educational grant from Lilly. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Steven Nissen, M.D., Chief Academic Officer of the Heart and Vascular Institute at the Cleveland Clinic and Professor of Medicine at the Clevland Clinic Lerner College of Medicine. Selected references: Nissen SE, Wolski K, Topol EJ. Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. JAMA. 2005;294:2581-2586 Kahn SE, Haffner SM, Heise MA, et al. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy (ADOPT). N Engl J Med 2006;355:2427­43. DREAM trial investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096 Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med 2007;356:2457-2471.